NZ614540B2 - Cathepsin c inhibitors - Google Patents
Cathepsin c inhibitors Download PDFInfo
- Publication number
- NZ614540B2 NZ614540B2 NZ614540A NZ61454012A NZ614540B2 NZ 614540 B2 NZ614540 B2 NZ 614540B2 NZ 614540 A NZ614540 A NZ 614540A NZ 61454012 A NZ61454012 A NZ 61454012A NZ 614540 B2 NZ614540 B2 NZ 614540B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- cycloalkyl
- compound
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title description 10
- 239000003112 inhibitor Substances 0.000 title description 6
- 102000005600 Cathepsins Human genes 0.000 title description 3
- 108010084457 Cathepsins Proteins 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 144
- 239000000203 mixture Substances 0.000 claims abstract description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 250
- 125000001072 heteroaryl group Chemical group 0.000 claims description 68
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 67
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 52
- 239000011780 sodium chloride Substances 0.000 claims description 52
- 125000003118 aryl group Chemical group 0.000 claims description 50
- 150000003839 salts Chemical class 0.000 claims description 47
- 125000003545 alkoxy group Chemical group 0.000 claims description 39
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 39
- 229910052736 halogen Inorganic materials 0.000 claims description 35
- 150000002367 halogens Chemical class 0.000 claims description 34
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 31
- 239000000546 pharmaceutic aid Substances 0.000 claims description 27
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 26
- 229910052757 nitrogen Inorganic materials 0.000 claims description 26
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 24
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 22
- 125000005418 aryl aryl group Chemical group 0.000 claims description 21
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 19
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 16
- 150000001602 bicycloalkyls Chemical group 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 14
- 125000001188 haloalkyl group Chemical group 0.000 claims description 12
- 125000003342 alkenyl group Chemical group 0.000 claims description 11
- 125000000304 alkynyl group Chemical group 0.000 claims description 11
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 11
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 11
- 125000003282 alkyl amino group Chemical group 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 125000005842 heteroatoms Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- 239000011593 sulfur Substances 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 102000003902 Cathepsin C Human genes 0.000 abstract description 44
- 108090000267 Cathepsin C Proteins 0.000 abstract description 44
- 201000010099 disease Diseases 0.000 abstract description 13
- 230000001404 mediated Effects 0.000 abstract description 7
- IMQYTQYAJQROAO-UHFFFAOYSA-N 4-aminobut-2-enamide Chemical class NCC=CC(N)=O IMQYTQYAJQROAO-UHFFFAOYSA-N 0.000 abstract description 2
- IVMRHVTWOHFAKG-WAVCKPEOSA-N 4-amino-N-[(E,3S)-6-(2,3-dihydroindol-1-yl)-6-oxohex-4-en-3-yl]oxane-4-carboxamide Chemical compound N([C@@H](CC)\C=C\C(=O)N1C2=CC=CC=C2CC1)C(=O)C1(N)CCOCC1 IVMRHVTWOHFAKG-WAVCKPEOSA-N 0.000 abstract 1
- -1 hydrocarbon radical Chemical class 0.000 description 102
- 239000000243 solution Substances 0.000 description 38
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 37
- 239000002904 solvent Substances 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
- 235000019439 ethyl acetate Nutrition 0.000 description 18
- 239000000543 intermediate Substances 0.000 description 18
- 239000011541 reaction mixture Substances 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- 125000004432 carbon atoms Chemical group C* 0.000 description 16
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 14
- 239000000843 powder Substances 0.000 description 13
- 239000000779 smoke Substances 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 12
- 210000004027 cells Anatomy 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 12
- 235000019504 cigarettes Nutrition 0.000 description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 11
- 125000001424 substituent group Chemical group 0.000 description 11
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000012453 solvate Substances 0.000 description 9
- PFKFTWBEEFSNDU-UHFFFAOYSA-N Carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 150000004677 hydrates Chemical class 0.000 description 8
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 8
- PAQZWJGSJMLPMG-UHFFFAOYSA-N propylphosphonic anhydride Substances CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 8
- 230000002829 reduced Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 102000012479 Serine Proteases Human genes 0.000 description 7
- 108010022999 Serine Proteases Proteins 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 210000004072 Lung Anatomy 0.000 description 6
- 210000000440 Neutrophils Anatomy 0.000 description 6
- 102000035443 Peptidases Human genes 0.000 description 6
- 108091005771 Peptidases Proteins 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 125000004429 atoms Chemical group 0.000 description 6
- 238000004166 bioassay Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229960004106 citric acid Drugs 0.000 description 6
- 235000015165 citric acid Nutrition 0.000 description 6
- 239000012230 colorless oil Substances 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrugs Drugs 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 125000001113 thiadiazolyl group Chemical group 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 229910010082 LiAlH Inorganic materials 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 230000001684 chronic Effects 0.000 description 5
- 230000001808 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drugs Drugs 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 239000003607 modifier Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 230000001225 therapeutic Effects 0.000 description 5
- 229960000583 Acetic Acid Drugs 0.000 description 4
- MGEVGECQZUIPSV-UHFFFAOYSA-N BOP reagent Chemical compound F[P-](F)(F)(F)(F)F.C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 MGEVGECQZUIPSV-UHFFFAOYSA-N 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 210000004969 Inflammatory Cells Anatomy 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 230000002378 acidificating Effects 0.000 description 4
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229960004592 isopropanol Drugs 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 125000004043 oxo group Chemical group O=* 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 3
- 208000006673 Asthma Diseases 0.000 description 3
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229940032147 Starch Drugs 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 235000008206 alpha-amino acids Nutrition 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 125000005059 halophenyl group Chemical group 0.000 description 3
- 239000008079 hexane Substances 0.000 description 3
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;N-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 200000000018 inflammatory disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 125000001786 isothiazolyl group Chemical group 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- NTNUDYROPUKXNA-UHFFFAOYSA-N methyl 2-(triphenyl-$l^{5}-phosphanylidene)acetate Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OC)C1=CC=CC=C1 NTNUDYROPUKXNA-UHFFFAOYSA-N 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 239000008184 oral solid dosage form Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 125000001715 oxadiazolyl group Chemical group 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 230000000699 topical Effects 0.000 description 3
- 125000001425 triazolyl group Chemical group 0.000 description 3
- PNFVIPIQXAIUAY-LURJTMIESA-N (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC[C@@H](C(O)=O)NC(=O)OC(C)(C)C PNFVIPIQXAIUAY-LURJTMIESA-N 0.000 description 2
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-Tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 2
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 2
- LPAGFVYQRIESJQ-UHFFFAOYSA-N 2,3-dihydro-1H-indole Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 2
- NIONDZDPPYHYKY-UHFFFAOYSA-N 2-hexenoic acid Chemical compound CCCC=CC(O)=O NIONDZDPPYHYKY-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 2
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 2
- 206010003246 Arthritis Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 206010006451 Bronchitis Diseases 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L Calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 108090000617 Cathepsin G Proteins 0.000 description 2
- 102000004173 Cathepsin G Human genes 0.000 description 2
- 208000007451 Chronic Bronchitis Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N Cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- 229940112141 Dry Powder Inhaler Drugs 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229940093915 Gynecological Organic acids Drugs 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 108010028275 Leukocyte Elastase Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 210000000138 Mast Cells Anatomy 0.000 description 2
- 229940071648 Metered Dose Inhaler Drugs 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- MDXGYYOJGPFFJL-QMMMGPOBSA-N N(α)-t-butoxycarbonyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)OC(C)(C)C MDXGYYOJGPFFJL-QMMMGPOBSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- CHKVPAROMQMJNQ-UHFFFAOYSA-M Potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 2
- 240000006394 Sorghum bicolor Species 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N Tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- CYRMSUTZVYGINF-UHFFFAOYSA-N Trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating Effects 0.000 description 2
- 230000002730 additional Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000001371 alpha-amino acids Chemical class 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 230000003078 antioxidant Effects 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 2
- 230000004059 degradation Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- OKKJLVBELUTLKV-VMNATFBRSA-N deuteriooxymethane Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 2
- 150000001975 deuterium Chemical group 0.000 description 2
- 125000004431 deuterium atoms Chemical group 0.000 description 2
- 229940009662 edetate Drugs 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- HPQVWDOOUQVBTO-UHFFFAOYSA-N lithium aluminium hydride Substances [Li+].[Al-] HPQVWDOOUQVBTO-UHFFFAOYSA-N 0.000 description 2
- OCZDCIYGECBNKL-UHFFFAOYSA-N lithium;alumanuide Chemical compound [Li+].[AlH4-] OCZDCIYGECBNKL-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 230000001603 reducing Effects 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 2
- 230000000391 smoking Effects 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 229960001367 tartaric acid Drugs 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-Heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- NPNPZTNLOVBDOC-UHFFFAOYSA-N 1,1-Difluoroethane Chemical compound CC(F)F NPNPZTNLOVBDOC-UHFFFAOYSA-N 0.000 description 1
- 125000006002 1,1-difluoroethyl group Chemical group 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dimercaptobutane-2,3-diol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-M 1-carboxynaphthalen-2-olate Chemical compound C1=CC=CC2=C(C([O-])=O)C(O)=CC=C21 UPHOPMSGKZNELG-UHFFFAOYSA-M 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- YURNCBVQZBJDAJ-UHFFFAOYSA-N 2-heptenoic acid Chemical compound CCCCC=CC(O)=O YURNCBVQZBJDAJ-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-M 3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoate Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GHOKWGTUZJEAQD-ZETCQYMHSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- LAPGMTOHOQPDGI-UHFFFAOYSA-N 4-amino-2,5-difluorobenzonitrile Chemical group NC1=CC(F)=C(C#N)C=C1F LAPGMTOHOQPDGI-UHFFFAOYSA-N 0.000 description 1
- 229940022663 Acetate Drugs 0.000 description 1
- 208000007474 Aortic Aneurysm Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229940009098 Aspartate Drugs 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 1
- 229940050390 Benzoate Drugs 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 210000003123 Bronchioles Anatomy 0.000 description 1
- 229940057971 Butane Drugs 0.000 description 1
- 210000001266 CD8-Positive T-Lymphocytes Anatomy 0.000 description 1
- 102100015176 CTSC Human genes 0.000 description 1
- 101710041552 CTSC Proteins 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N C[N+](C)(C)CCO Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N Camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 210000000845 Cartilage Anatomy 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- 102000003858 Chymases Human genes 0.000 description 1
- 108090000227 Chymases Proteins 0.000 description 1
- 229960000913 Crospovidone Drugs 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 210000003298 Dental Enamel Anatomy 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N Dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- UMNKXPULIDJLSU-UHFFFAOYSA-N Dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 description 1
- 229940087091 Dichlorotetrafluoroethane Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- RWRIWBAIICGTTQ-UHFFFAOYSA-N Difluoromethane Chemical compound FCF RWRIWBAIICGTTQ-UHFFFAOYSA-N 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N Dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 101700035153 EER5 Proteins 0.000 description 1
- 102100003966 ELANE Human genes 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 229940088598 Enzyme Drugs 0.000 description 1
- 210000000981 Epithelium Anatomy 0.000 description 1
- 229950000206 Estolate Drugs 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N Ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 210000002744 Extracellular Matrix Anatomy 0.000 description 1
- 229940077203 Fatal-Plus Drugs 0.000 description 1
- 101700054771 GCA Proteins 0.000 description 1
- 102100010305 GLI2 Human genes 0.000 description 1
- 101700036688 GLI2 Proteins 0.000 description 1
- 229960001731 GLUCEPTATE Drugs 0.000 description 1
- 229940049906 Glutamate Drugs 0.000 description 1
- 102000001398 Granzymes Human genes 0.000 description 1
- 108060005986 Granzymes Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- LJQLCJWAZJINEB-UHFFFAOYSA-N Hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F LJQLCJWAZJINEB-UHFFFAOYSA-N 0.000 description 1
- NNPPMTNAJDCUHE-UHFFFAOYSA-N Isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 1
- 229940119837 Isopropyl Alcohol Drugs 0.000 description 1
- 102100011337 KLK4 Human genes 0.000 description 1
- 210000000822 Killer Cells, Natural Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 229940001447 Lactate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N Lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 210000003712 Lysosomes Anatomy 0.000 description 1
- 101700061402 MTRX Proteins 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- 230000035633 Metabolized Effects 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 210000001331 Nose Anatomy 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N Octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229940055729 Papain Drugs 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- GTLACDSXYULKMZ-UHFFFAOYSA-N Pentafluoroethane Chemical compound FC(F)C(F)(F)F GTLACDSXYULKMZ-UHFFFAOYSA-N 0.000 description 1
- 229950003332 Perflubutane Drugs 0.000 description 1
- KAVGMUDTWQVPDF-UHFFFAOYSA-N Perfluorobutane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F KAVGMUDTWQVPDF-UHFFFAOYSA-N 0.000 description 1
- 241000144952 Peromyscus californicus Species 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940069328 Povidone Drugs 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 206010038683 Respiratory disease Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 206010039083 Rhinitis Diseases 0.000 description 1
- 101710017884 Segment-8 Proteins 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical class OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 101700070494 THP1 Proteins 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 229950002757 Teoclate Drugs 0.000 description 1
- 210000003437 Trachea Anatomy 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229940046009 Vitamin E Drugs 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- IBUKXRINTKQBRQ-FOENULIHSA-N [(2R)-2-hexadecanoyloxy-3-[hydroxy-[(2R,3R,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OC1[C@H](O)[C@@H](O)C(O)[C@@H](O)[C@H]1O IBUKXRINTKQBRQ-FOENULIHSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012042 active reagent Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000005466 alkylenyl group Chemical group 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M caproate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N cdcl3 Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- LKYXEULZVGJVTG-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH] LKYXEULZVGJVTG-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 201000009151 chronic rhinitis Diseases 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940099364 dichlorofluoromethane Drugs 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N ethyl amine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- SAVROPQJUYSBDD-UHFFFAOYSA-N formyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)=CO SAVROPQJUYSBDD-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-L galactarate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C([O-])=O DSLZVSRJTYRBFB-DUHBMQHGSA-L 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000009114 investigational therapy Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-M isethionate Chemical compound OCCS([O-])(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-M 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 229940035415 isobutane Drugs 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 108010024383 kallikrein 4 Proteins 0.000 description 1
- 230000002147 killing Effects 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000003591 leukocyte elastase inhibitor Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- OCZDCIYGECBNKL-HGZFDWPVSA-N lithium;tetradeuterioalumanuide Chemical compound [Li+].[2H][Al-]([2H])([2H])[2H] OCZDCIYGECBNKL-HGZFDWPVSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000001868 lysosomic Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 230000000873 masking Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001576 membenolytic Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- IQQDLHGWGKEQDS-UHFFFAOYSA-N methyl hept-2-enoate Chemical compound CCCCC=CC(=O)OC IQQDLHGWGKEQDS-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 101700045377 mvp1 Proteins 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 231100000043 nose-only exposure Toxicity 0.000 description 1
- 230000001473 noxious Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- LVSJDHGRKAEGLX-UHFFFAOYSA-N oxolane;2,2,2-trifluoroacetic acid Chemical compound C1CCOC1.OC(=O)C(F)(F)F LVSJDHGRKAEGLX-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229960004692 perflenapent Drugs 0.000 description 1
- NJCBUSHGCBERSK-UHFFFAOYSA-N perfluoropentane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F NJCBUSHGCBERSK-UHFFFAOYSA-N 0.000 description 1
- 229960004065 perflutren Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004977 physiological function Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002797 proteolythic Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 230000000452 restraining Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000001730 thiiranyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 125000005490 tosylate group Chemical class 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N α-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Disclosed herein are compounds of Formula (I) which are 4-amino-2-butenamides, where the subtituents are as defined herein. An example of these compounds being 4-amino-N-[(1S,2E)-4-(2,3-dihydro-1H-indol-1-yl)-1-ethyl-4-oxo-2-buten-1-yl]tetrahydro-2H-pyran-4-carboxamide. Also disclosed are pharmaceutical compositions containing these compounds which are useful for the treatment of diseases mediated by the cathepsin C enzyme such as chronic obstructive pulmonary disease. ical compositions containing these compounds which are useful for the treatment of diseases mediated by the cathepsin C enzyme such as chronic obstructive pulmonary disease.
Description
PU64508
Cathepsin C Inhibitors
This application claims the benefit of U.S. Provisional Application No. 61/441840
filed on 11 February 2011, which is incorporated herein in its entirety.
FIELD OF THE INVENTION
The present invention relates to certain 4-aminobutenamides that are cathepsin
C inhibitors, pharmaceutical compositions containing these compounds, and their use in
the treatment of diseases mediated by the cathepsin C enzyme such as chronic obstructive
pulmonary disease.
BACKGROUND OF THE INVENTION
Cathepsins are a family of enzymes included in the papain superfamily of cysteine
proteases. Cathepsins B, C, F, H, K, L, S, V, and X have been described in the scientific
literature. Cathepsin C is also known in the literature as Dipeptidyl Peptidase I or
"DPPI."
A number of recently published studies have begun to describe the role cathepsin
C plays in certain inflammatory processes. See e.g. Adkison et al., The Journal of
Clinical Investigation 109:363-371 (2002); Tran et al., Archives of Biochemistry and
Biophysics 403:160-170 (2002); Thiele et al., The Journal of Immunology 158: 5200-
5210 (1997); Bidere et al., The Journal of Biological Chemistry 277: 32339-32347
(2002); Mabee et al., The Journal of Immunology 160: 5880-5885; McGuire et al., The
Journal of Biological Chemistry, 268: 2458-2467; and Paris et al., FEBS Letters 369:
326-330 (1995). From these studies, it appears that cathepsin C is co-expressed in
granules with certain serine proteases and functions to process the pro-forms of these
proteases to active forms, which are then released from the granules of inflammatory cells
recruited to sites of inflammation. Once activated, these proteases have a number of
functions including degradation of various extracellular matrix components, which
together can propagate tissue damage and chronic inflammation.
For example, Chronic Obstructive Pulmonary Disease ("COPD") is a chronic
inflammatory disease where cathepsin C appears to play a role. Chronic bronchitis and
emphysema usually occur together in COPD patients. Chronic bronchitis is generally
PU64508
characterized by a chronic productive cough, whereas emphysema is generally
characterized by permanent enlargement of the airspaces distal to the terminal
bronchioles and airway wall destruction.
Cigarette smoking is a significant risk factor for developing COPD. Exposure to
cigarette smoke and other noxious particles and gases may result in chronic inflammation
of the lung. In response to such exposure, inflammatory cells such as CD8+ T cells,
macrophages, and neutrophils are recruited to the area. These recruited inflammatory
cells release proteases, which are believed to play a major role in the disease etiology by a
number of mechanisms. Proteases believed to be involved in this process include the
serine proteases neutrophil elastase ("NE"), cathepsin G, and proteinase 3, all released
from neutrophils; granzymes A and B, released from cytotoxic T cells or natural killer
cells; and chymases, released from mast cells. Cathepsin C appears to be involved in
activating all of these enzymes. Additionally, cathepsin C knockout mice are resistant to
lung airspace enlargement and inflammatory cell infiltration in both cigarette smoke and
ozone exposure models of COPD. See Guay et al., Current Topics in Medicinal
Chemistry, 2010, 10, 708-716; See also Podolin et al. (2008), Inflammation Research,
57(Suppl 2) S104.
Rheumatoid arthritis ("RA") is another chronic inflammatory disease where
cathepsin C may play a role. Neutrophils are recruited to the site of joint inflammation
and release cathepsin G, NE, and proteinase 3, which are believed to be responsible in
part for cartilage destruction associated with RA (Hu, Y. and Pham, C. T. (2005) Arthritis
Rheum 52: 2553-2558).
Other conditions where cathepsin C may play a role include osteoarthritis, asthma,
and Multiple Sclerosis. See e.g. Matsui, K.; Yuyama, N.; Akaiwa, M.; Yoshida, N. L.;
Maeda, M.; Sugita, Y.; Izuhara, K., Identification of an alternative splicing variant of
cathepsin C/dipeptidyl-peptidase I, Gene. 293(1-2):1-7, 2002 Jun 26; Wolters, P. J.; Laig-
Webster, M.; Caughey, G. H., Dipeptidyl peptidase I cleaves matrix-associated proteins
and is expressed mainly by mast cells in normal dog airways, American Journal of
Respiratory Cell & Molecular Biology. 22(2):183-90, 2000.
One approach to treating these conditions is to inhibit the activity of the serine
proteases involved in the inflammatory process, especially NE activity. See e.g.,
Ohbayashi, "Neutrophil elastase inhibitors as treatment for COPD", Expert Opin.
PU64508
Investig. Drugs 11(7): 965-980 (2002); Shapiro, "Neutrophil Elastase: Path Clearer,
Pathogen Killer, or Just Pathologic?", Am. J. Respir. Cell Mol. Biol. 26: 266-268 (2002).
In light of the role cathepsin C plays in activating certain serine proteases, especially NE,
it is desirable to prepare compounds that inhibit its activity, which thereby inhibit serine
protease activity. Thus, there is a need to identify compounds that inhibit cathepsin C,
which can be used in the treatment of a variety of conditions mediated by cathepsin C.
There are additional activities of cathepsin C that may also be related to disease
etiology. Cathepsin C has been demonstrated to have a role in neutrophil migration in the
development of aortic aneurysms by a mechanism which has not been clearly elucidated
(Pagano, M. B. et al. (2007) PNAS 104: 2855-2860). Thus, disease processes that
involve neutrophil migration, as well as proteolytic enzyme release can be modulated by
cathepsin C inhibition. Also, cathepsin C is highly expressed in the lung epithelium
where it may play a role in the processing of other enzymes not yet identified. Cathepsin
C has also been reported to cleave kallikrein-4, which is believed to play a role in dental
enamel maturation (Tye, C. E. et al. (2009) J. Dental Res. 88: 323-327). Finally,
cathepsin C is itself released from cells and may play a direct role in the degradation of
matrix proteins.
SUMMARY OF THE INVENTION
The present invention involves novel compounds according to Formula (I) or a
pharmaceutically acceptable salt thereof:
HN N
O R R
wherein:
R and R are each independently selected from the group consisting of hydrogen,
(C -C )alkyl, (C -C )alkenyl, (C -C )alkynyl, (C -C )cycloalkyl, (C -C )cycloalkenyl,
1 8 2 8 2 8 3 8 5 8
(C -C )bicycloalkyl, heterocycloalkyl, (C -C )cycloalkyl(C -C )alkyl,
6 10 3 8 1 6
(C -C )cycloalkenyl(C -C )alkyl, heterocycloalkyl(C -C )alkyl, aryl, heteroaryl,
8 1 6 1 6
aryl(C -C )alkyl, and heteroaryl(C -C )alkyl;
1 6 1 6
PU64508
wherein any (C -C )alkyl, (C -C )alkenyl, or (C -C )alkynyl is optionally
1 8 2 8 2 8
substituted one to three times, independently, by -CF , cyano, -CO (C -C )alkyl,
3 2 1 4
-CONH(C -C )alkyl, -CON(C -C )alkyl(C -C )alkyl, -SO (C -C )alkyl,
1 4 1 4 1 4 2 1 4
-SO NH(C -C )alkyl, -SO N(C -C )alkyl(C -C )alkyl, amino, (C -C )alkylamino,
2 1 4 2 1 4 1 4 1 4
((C -C )alkyl)((C -C )alkyl)amino, hydroxyl, or (C -C )alkoxy;
1 4 1 4 1 4
and wherein any cycloalkyl, cycloalkenyl, bicycloalkyl, or
heterocycloalkyl group is optionally substituted one to three times, independently,
by (C -C )alkyl, (C -C )haloalkyl, cyano, -CO (C -C )alkyl, -CONH(C -C )alkyl,
1 4 1 4 2 1 4 1 4
-CON(C -C )alkyl(C -C )alkyl, -SO (C -C )alkyl, -SO NH(C -C )alkyl,
1 4 1 4 2 1 4 2 1 4
-SO N(C -C )alkyl(C -C )alkyl, amino, (C -C )alkylamino,
2 1 4 1 4 1 4
((C -C )alkyl)((C -C )alkyl)amino, hydroxyl, (C -C )alkoxy, aryl, or
1 4 1 4 1 4
aryl(C -C )alkyl, wherein the aryl moiety of said aryl or aryl(C -C )alkyl is
1 4 1 4
optionally substituted one to three times, independently, by halogen, -CF ,
(C -C )alkyl, hydroxyl, or (C -C )alkoxy;
1 4 1 4
and wherein any aryl or heteroaryl group is optionally substituted one to
three times, independently, by halogen, (C -C )alkyl, (C -C )cycloalkyl,
1 6 3 6
(C -C )cycloalkenyl, (C -C )haloalkyl, cyano, -CO (C -C )alkyl,
6 1 6 2 1 4
-CONH(C -C )alkyl, -CON(C -C )alkyl(C -C )alkyl, -SO (C -C )alkyl,
1 4 1 4 1 4 2 1 4
-SO NH(C -C )alkyl, -SO N(C -C )alkyl(C -C )alkyl, amino, (C -C )alkylamino,
2 1 4 2 1 4 1 4 1 4
((C -C )alkyl)((C -C )alkyl)amino, hydroxyl, (C -C )alkoxy, (C -C )alkylthio-,
1 4 1 4 1 4 1 4
aryl, heteroaryl, aryl(C -C )alkyl, or heteroaryl(C -C )alkyl;
1 4 1 4
wherein any aryl or heteroaryl moiety of said aryl, heteroaryl,
aryl(C -C )alkyl, or heteroaryl(C -C )alkyl is optionally substituted one to
1 4 1 4
three times, independently, by halogen, -CF , (C -C )alkyl, hydroxyl, or
3 1 4
(C -C )alkoxy;
and wherein any (C -C )cycloalkyl is optionally substituted one to
three times, independently, by (C -C )alkyl, aryl, or heteroaryl;
wherein said aryl or heteroaryl is optionally substituted one
to three times, independently, by halogen, -CF , (C -C )alkyl,
3 1 4
hydroxyl, or (C -C )alkoxy;
or R and R taken together with the nitrogen to which they are attached represent
a 5- to 7-membered saturated or unsaturated ring optionally containing one other
PU64508
heteroatom which is oxygen, nitrogen, or sulfur, wherein said ring is optionally fused to a
(C -C )cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
or R and R taken together with the nitrogen to which they are attached represent
a 6- to 10-membered bridged bicyclic ring system optionally fused to a (C -C )cycloalkyl,
heterocycloalkyl, aryl, or heteroaryl ring; and
R is hydrogen, (C -C )alkyl, (C -C )haloalkyl, (C -C )alkenyl, (C -C )alkynyl,
1 8 1 8 2 8 2 8
(C -C )cycloalkyl, (C -C )cycloalkenyl, (C -C )cycloalkyl(C -C )alkyl,
3 6 5 6 3 6 1 4
(C -C )cycloalkenyl(C -C )alkyl, or aryl(C -C )alkyl, wherein the aryl moiety of the
6 1 4 1 4
aryl(C -C )alkyl is optionally substituted one to three times, independently, by halogen,
(C -C )alkyl, or -CF .
1 4 3
Also described herein is the use of a compound of Formula (I) or a
pharmaceutically acceptable salt thereof in the prevention, management or treatment of a
respiratory or inflammatory disease, such as chronic obstructive pulmonary disease or
rhinitis.
In a further aspect, this invention relates to a pharmaceutically acceptable
formulation comprising a compound of Formula (I) or a pharmaceutically acceptable salt
thereof and a pharmaceutically acceptable excipient.
In a further aspect, this invention relates to the use of a compound of Formula (I)
or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use
in the treatment of chronic obstructive pulmonary disease.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 shows the accumulation of total leukocytes in the Bronchoalveolar Lavage Fluid of
C57BL/6 Mice following twice daily oral administration of the compounds of Example 1
and 2 at the indicated doses for the final 6 weeks during 18 weeks of cigarette smoke
exposure.
Fig. 2 shows the accumulation of neutrophils in the Bronchoalveolar Lavage Fluid of
C57BL/6 Mice following twice daily oral administration of the compounds of Example 1
and 2 at the indicated doses for the final 6 weeks during 18 weeks of cigarette smoke
exposure.
PU64508
Fig. 3 shows the accumulation of mononuclear cells in the Bronchoalveolar Lavage Fluid
of C57BL/6 Mice following twice daily oral administration of the compounds of Example
1 and 2 at the indicated doses for the final 6 weeks during 18 weeks of cigarette smoke
exposure.
DETAILED DESCRIPTION OF THE INVENTION
Terms and Definitions
As used herein, the term “alkyl” refers to a straight- or branched-chain
hydrocarbon radical having the specified number of carbon atoms. As used herein, the
terms “(C -C )alkyl” and “(C -C )alkyl” refer to an alkyl group having at least 1 and up
1 4 1 8
to 4 or 8 carbon atoms respectively. Examples of such branched or straight-chained alkyl
groups useful in the present invention include, but are not limited to, methyl, ethyl,
n-propyl, isopropyl, n-butyl, isobutyl, s-butyl, t-butyl, n-pentyl, isopentyl, n-hexyl,
n-heptyl, n-octyl, and branched analogs of the latter 3 normal alkanes.
When the term "alkyl" is used in combination with other substituent groups, such
as “(C -C )haloalkyl" or “aryl(C -C )alkyl”, the term "alkyl" is intended to encompass a
1 4 1 4
divalent straight or branched-chain hydrocarbon radical, wherein the point of attachment
is through the alkyl moiety. Examples of “(C -C )haloalkyl" groups useful in the present
invention include, but are not limited to, -CF (trifluoromethyl), -CCl (trichloromethyl),
1,1-difluoroethyl, 2,2,2-trifluoroethyl, and hexafluoroisopropyl. Examples of “aryl(C -
C )alkyl " groups useful in the present invention include, but are not limited to, benzyl
(phenylmethyl), 1-methylbenzyl (1-phenylethyl), 1,1-dimethylbenzyl
(1-phenylisopropyl), and phenethyl (2-phenylethyl).
As used herein, the term "alkenyl" refers to straight or branched hydrocarbon
chains containing the specified number of carbon atoms and at least 1 and up to 3 carbon-
carbon double bonds. Examples include ethenyl and propenyl.
As used herein, the term "alkynyl" refers to straight or branched hydrocarbon
chains containing the specified number of carbon atoms and at least 1 and up to 3 carbon-
carbon triple bonds. Examples include ethynyl and propynyl.
As used herein, the term “cycloalkyl” refers to a non-aromatic, saturated, cyclic
hydrocarbon ring containing the specified number of carbon atoms. The term
“(C -C )cycloalkyl” refers to a non-aromatic cyclic hydrocarbon ring having from three
PU64508
to eight ring carbon atoms. Exemplary “(C -C )cycloalkyl” groups useful in the present
invention include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and
cyclooctyl.
As used herein, the term “cycloalkenyl” refers to a non-aromatic, cyclic
hydrocarbon ring containing the specified number of carbon atoms and at least one
carbon-carbon double bond. The term “(C -C )cycloalkenyl” refers to a non-aromatic
cyclic hydrocarbon ring having from five to eight ring carbon atoms. Exemplary
“(C -C )cycloalkenyl” groups useful in the present invention include cyclopentenyl,
cyclohexenyl, cycloheptenyl, and cyclooctenyl.
As used herein, the term “bicycloalkyl” refers to a saturated, bridged, bicyclic
hydrocarbon ring system containing the specified number of carbon atoms. The term
“(C -C )bicycloalkyl” refers to a bicyclic hydrocarbon ring system having from six to ten
6 10
carbon atoms. Exemplary “(C -C )bicycloalkyl” groups useful in the present invention
6 10
include bicyclo[2.1.1]hexyl, bicyclo[2.1.1]heptyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl,
bicyclo[3.2.2]nonyl, bicyclo[3.3.1]nonyl, bicyclo[3.3.2]decyl, and bicyclo[4.3.1]decyl.
“Alkoxy” means an alkyl radical containing the specified number of carbon atoms
attached through an oxygen linking atom. The term “(C -C )alkoxy” refers to a straight-
or branched-chain hydrocarbon radical having at least 1 and up to 4 carbon atoms
attached through an oxygen linking atom. Exemplary “(C -C )alkoxy” groups useful in
the present invention include, but are not limited to, methoxy, ethoxy, n-propoxy,
isopropoxy, n-butoxy, s-butoxy, and t-butoxy.
“Alkylthio-” means an alkyl radical containing the specified number of carbon
atoms attached through a sulfur linking atom. The term “(C -C )alkylthio-” refers to a
straight- or branched-chain hydrocarbon radical having at least 1 and up to 4 carbon
atoms attached through a sulfur linking atom. Exemplary “(C -C )alkylthio-” groups
useful in the present invention include, but are not limited to, methylthio-, ethylthio-,
n-propylthio-, isopropylthio-, n-butylthio-, s-butylthio-, and t-butylthio-.
“Heterocycloalkyl” means a non-aromatic heterocyclic ring containing 3-8 or 5-6
ring atoms, being saturated or having one or more degrees of unsaturation and containing
one or more heteroatom substitutions selected from O, S, and/or N. Such a ring may be
optionally fused to one or more other heterocycloalkyl ring(s) or cycloalkyl ring(s).
Examples of “heterocycloalkyl” moieties include, but are not limited to, aziridinyl,
PU64508
thiiranyl, oxiranyl, azetidinyl, oxetanyl, thietanyl, tetrahydrofuranyl, dihydropyranyl,
tetrahydropyranyl, 1,4-dioxanyl, 1,3-dioxanyl, piperidinyl, piperazinyl,
2,4-piperazinedionyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, pyrazolidinyl, pyrazolinyl,
morpholinyl, thiomorpholinyl, tetrahydrothiopyranyl, tetrahydrothienyl, and the like.
“Aryl” refers to optionally substituted monocyclic or fused bicyclic groups having
6 to 14 carbon atoms and having at least one aromatic ring that complies with Hückel's
Rule. Examples of “aryl” groups are phenyl, naphthyl, indenyl, dihydroindenyl,
anthracenyl, phenanthrenyl, and the like. “Heteroaryl” means an optionally substituted
aromatic monocyclic ring or fused bicyclic ring system wherein at least one ring complies
with Hückel's Rule, has the specified number of ring atoms, and that ring contains at least
one heteroatom selected from N, O, and/or S. Examples of 5-membered “heteroaryl”
groups include furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl,
thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, and isothiazolyl. Examples of
6-membered “heteroaryl” groups include oxo-pyridyl, pyridinyl, pyridazinyl, pyrazinyl,
and pyrimidinyl. Examples of 6,6-fused “heteroaryl” groups include quinolinyl,
isoquinolinyl, quinoxalinyl, cinnolinyl, phthalazinyl, quinazolinyl, 1,5-naphthyridinyl,
1,6-naphthyridinyl, 1,7-naphthyridinyl, 1,8-naphthyridinyl, and pteridinyl. Examples of
6,5-fused “heteroaryl” groups include benzofuranyl, benzothienyl, benzimidazolyl,
benzthiazolyl, indolizinyl, indolyl, isoindolyl, and indazolyl.
For the avoidance of doubt, all bicyclic ring systems may be attached at any
suitable position on either ring.
As used herein, “halogen” or “halo” refers to F, Cl, Br, or I.
"Optionally substituted" indicates that a group, such as alkyl, alkenyl, alkynyl,
cycloalkyl, cycloalkenyl, bicycloalkyl, alkoxy, heterocycloalkyl, aryl, or heteroaryl, may
be unsubstituted, or the group may be substituted with one or more substituent(s) as
defined. In the case where groups may be selected from a number of alternative groups
the selected groups may be the same or different.
The term “independently” means that where more than one substituent is selected
from a number of possible substituents, those substituents may be the same or different.
That is, each substituent is separately selected from the entire group of recited possible
substituents (e.g. a group of substituents provided herein for various aryl or heteroaryl is
halogen, -CF , (C -C )alkyl, hydroxyl, and (C -C )alkoxy).
3 1 4 1 4
PU64508
The alternative definitions for the various groups and substituent groups of
Formula (I) provided throughout the specification are intended to particularly describe
each compound species disclosed herein, individually, as well as groups of one or more
compound species. The scope of this invention includes any combination of these group
and substituent group definitions. The compounds of the invention are only those which
are contemplated to be “chemically stable” as will be appreciated by those skilled in the
art.
Suitably, R and R are each independently selected from the group consisting of
hydrogen, (C -C )alkyl, (C -C )alkenyl, (C -C )alkynyl, (C -C )cycloalkyl, (C -
1 8 2 8 2 8 3 8 5
C )cycloalkenyl, (C -C )bicycloalkyl, heterocycloalkyl, (C -C )cycloalkyl(C -C )alkyl,
8 6 10 3 8 1 6
(C -C )cycloalkenyl(C -C )alkyl, heterocycloalkyl(C -C )alkyl, aryl, heteroaryl,
8 1 6 1 6
aryl(C -C )alkyl, and heteroaryl(C -C )alkyl;
1 6 1 6
wherein any (C -C )alkyl, (C -C )alkenyl, or (C -C )alkynyl is optionally
1 8 2 8 2 8
substituted one to three times, independently, by -CF , cyano, -CO (C -C )alkyl,
3 2 1 4
-CONH(C -C )alkyl, -CON(C -C )alkyl(C -C )alkyl, -SO (C -C )alkyl,
1 4 1 4 1 4 2 1 4
-SO NH(C -C )alkyl, -SO N(C -C )alkyl(C -C )alkyl, amino, (C -C )alkylamino,
2 1 4 2 1 4 1 4 1 4
((C -C )alkyl)((C -C )alkyl)amino, hydroxyl, or (C -C )alkoxy;
1 4 1 4 1 4
and wherein any cycloalkyl, cycloalkenyl, bicycloalkyl, or
heterocycloalkyl group is optionally substituted one to three times, independently,
by (C -C )alkyl, (C -C )haloalkyl, cyano, -CO (C -C )alkyl, -CONH(C -C )alkyl,
1 4 1 4 2 1 4 1 4
-CON(C -C )alkyl(C -C )alkyl, -SO (C -C )alkyl, -SO NH(C -C )alkyl,
1 4 1 4 2 1 4 2 1 4
-SO N(C -C )alkyl(C -C )alkyl, amino, (C -C )alkylamino,
2 1 4 1 4 1 4
((C -C )alkyl)((C -C )alkyl)amino, hydroxyl, (C -C )alkoxy, aryl, or
1 4 1 4 1 4
aryl(C -C )alkyl; wherein the aryl moiety of said aryl or aryl(C -C )alkyl is
1 4 1 4
optionally substituted one to three times, independently, by halogen, -CF ,
(C -C )alkyl, hydroxyl, or (C -C )alkoxy;
1 4 1 4
and wherein any aryl or heteroaryl group is optionally substituted one to
three times, independently, by halogen, (C -C )alkyl, (C -C )cycloalkyl,
1 6 3 6
(C -C )cycloalkenyl, (C -C )haloalkyl, cyano, -CO (C -C )alkyl,
6 1 6 2 1 4
-CONH(C -C )alkyl, -CON(C -C )alkyl(C -C )alkyl, -SO (C -C )alkyl,
1 4 1 4 1 4 2 1 4
-SO NH(C -C )alkyl, -SO N(C -C )alkyl(C -C )alkyl, amino, (C -C )alkylamino,
2 1 4 2 1 4 1 4 1 4
PU64508
((C -C )alkyl)((C -C )alkyl)amino, hydroxyl, (C -C )alkoxy, (C -C )alkylthio-,
1 4 1 4 1 4 1 4
aryl, heteroaryl, aryl(C -C )alkyl, or heteroaryl(C -C )alkyl;
1 4 1 4
wherein any aryl or heteroaryl moiety of said aryl, heteroaryl,
aryl(C -C )alkyl, or heteroaryl(C -C )alkyl is optionally substituted one to
1 4 1 4
three times, independently, by halogen, -CF , (C -C )alkyl, hydroxyl, or
3 1 4
(C -C )alkoxy;
and wherein any (C -C )cycloalkyl is optionally substituted one to
three times, independently, by (C -C )alkyl, aryl, or heteroaryl;
wherein said aryl or heteroaryl is optionally substituted one
to three times, independently, by halogen, -CF , (C -C )alkyl,
3 1 4
hydroxyl, or (C -C )alkoxy.
In another embodiment, R and R are each independently selected from the group
consisting of hydrogen, (C -C )alkyl, (C -C )cycloalkyl, (C -C )bicycloalkyl,
1 6 3 7 7 9
heterocycloalkyl, (C -C )cycloalkyl(C -C )alkyl, phenyl, heteroaryl, phenyl(C -C )alkyl,
3 7 1 4 1 4
and heteroaryl(C -C )alkyl;
wherein any (C -C )alkyl group is optionally substituted one to three
times, independently, by (C -C )cycloalkyl, -CF , cyano, -CO (C -C )alkyl,
3 6 3 2 1 4
hydroxyl, or (C -C )alkoxy;
and wherein any cycloalkyl, bicycloalkyl, or heterocycloalkyl group is
optionally substituted one to three times, independently, by (C -C )alkyl, -CF ,
1 4 3
cyano, -CO (C -C )alkyl, hydroxyl, (C -C )alkoxy, phenyl, or phenyl(C -C )alkyl;
2 1 4 1 4 1 2
wherein the phenyl moiety of said phenyl or phenyl(C -C )alkyl is optionally
substituted one to three times, independently, by halogen, -CF , (C -C )alkyl,
3 1 4
hydroxyl, or (C -C )alkoxy;
and wherein any phenyl or heteroaryl group is optionally substituted one to
three times, independently, by halogen, (C -C )alkyl, (C -C )cycloalkyl, -CF ,
1 6 3 6 3
cyano, -CO (C -C )alkyl, -SO (C -C )alkyl, hydroxyl, (C -C )alkoxy, (C -
2 1 4 2 1 4 1 4 1
C )alkylthio-, phenyl, heteroaryl, phenyl(C -C )alkyl, or heteroaryl(C -C )alkyl;
4 1 4 1 4
wherein any phenyl or heteroaryl moiety of said phenyl, heteroaryl,
phenyl(C -C )alkyl, or heteroaryl(C -C )alkyl is optionally substituted one
1 4 1 4
to three times, independently, by halogen, -CF , or (C -C )alkyl;
3 1 4
PU64508
and wherein any (C -C )cycloalkyl is optionally substituted one to
three times, independently, by (C -C )alkyl, phenyl, or heteroaryl;
wherein said phenyl or heteroaryl is optionally substituted
one to three times, independently, by halogen, -CF , or
(C -C )alkyl.
In a further embodiment, R is selected from the group consisting of (C -C )alkyl,
(C -C )cycloalkyl, (C -C )bicycloalkyl, heterocycloalkyl, (C -C )cycloalkyl(C -C )alkyl,
3 7 7 9 3 7 1 2
phenyl, heteroaryl, and phenyl(C -C )alkyl; wherein any cycloalkyl or heterocycloalkyl
group is optionally substituted one to two times, independently, by (C -C )alkyl, -CF ,
1 4 3
hydroxyl, or (C -C )alkoxy, and wherein any phenyl or heteroaryl group is optionally
substituted one to two times, independently, by halogen, (C -C )alkyl, -CF , cyano,
1 4 3
-CO (C -C )alkyl, hydroxyl, (C -C )alkoxy, or (C -C )alkylthio-. In yet a further
2 1 4 1 4 1 4
embodiment, R is phenyl optionally substituted one to two times, independently, by
halogen, (C -C )alkyl, -CF , cyano, -CO (C -C )alkyl, hydroxyl, (C -C )alkoxy, or
1 4 3 2 1 4 1 4
(C -C )alkylthio-. In yet a further embodiment, R is furanyl, thienyl, pyrrolyl,
imidazolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl,
thiadiazolyl, or isothiazolyl optionally substituted by halogen, (C -C )alkyl, -CF ,
1 4 3
(C -C )cycloalkyl, phenyl, halophenyl, phenyl(C -C )alkyl, halophenyl(C -C )alkyl,
3 6 1 4 1 4
cyano, -CO (C -C )alkyl, (C -C )alkoxy, or (C -C )alkylthio-; wherein said
2 1 4 1 4 1 4
(C -C )cycloalkyl is optionally substituted by (C -C )alkyl. In yet a further embodiment,
3 6 1 4
R is thiadiazolyl optionally substituted by halogen, (C -C )alkyl, -CF ,
1 4 3
(C -C )cycloalkyl, phenyl, halophenyl, phenyl(C -C )alkyl, cyano, -CO (C -C )alkyl,
3 6 1 4 2 1 4
(C -C )alkoxy, or (C -C )alkylthio-; wherein said (C -C )cycloalkyl is optionally
1 4 1 4 3 6
substituted by (C -C )alkyl. In yet a further embodiment, R is thiadiazolyl optionally
substituted by halogen, (C -C )alkyl, -CF , (C -C )cycloalkyl, phenyl, cyano,
1 4 3 3 6
-CO (C -C )alkyl, or (C -C )alkoxy; wherein said (C -C )cycloalkyl is optionally
2 1 4 1 4 3 6
substituted by (C -C )alkyl. In selected embodiments, R is 5-cyclohexyl-1,3,4-
thiadiazolyl or 5-phenyl-1,3,4-thiadiazolyl.
In another embodiment, R is hydrogen or (C -C )alkyl. In selected embodiments,
R is hydrogen or methyl. In another selected embodiment, R is hydrogen.
In another embodiment, R and R taken together with the nitrogen to which they
are attached represent a 5- to 7-membered saturated or unsaturated ring optionally
PU64508
containing one other heteroatom which is oxygen, nitrogen, or sulfur; wherein said ring is
optionally fused to a (C -C )cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring. In a
further embodiment, R and R taken together with the nitrogen to which they are
attached represent a 5- to 6-membered saturated or unsaturated ring optionally fused to a
phenyl moiety. In a selected embodiment, R and R taken together with the nitrogen to
which they are attached represent 1H-indolyl or 2,3-dihydro-1H-indolyl. In another
selected embodiment, R and R taken together with the nitrogen to which they are
attached represent 2,3-dihydro-1H-indolyl.
In another embodiment, R and R taken together with the nitrogen to which they
are attached represent a 6- to 10-membered bridged bicyclic ring system optionally fused
to a (C -C )cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring. In a further
embodiment, R and R taken together with the nitrogen to which they are attached
represent a 7- to 9-membered bridged bicyclic ring system optionally fused to a phenyl
moiety.
Suitably, R is hydrogen, (C -C )alkyl, (C -C )haloalkyl, (C -C )alkenyl,
1 8 1 8 2 8
(C -C )alkynyl, (C -C )cycloalkyl, (C -C )cycloalkenyl, (C -C )cycloalkyl(C -C )alkyl,
2 8 3 6 5 6 3 6 1 4
(C -C )cycloalkenyl(C -C )alkyl, or aryl(C -C )alkyl; wherein the aryl moiety of the
6 1 4 1 4
aryl(C -C )alkyl is optionally substituted one to three times, independently, by halogen,
(C -C )alkyl, or -CF .
1 4 3
In another embodiment, R is hydrogen, (C -C )alkyl, (C -C )haloalkyl,
1 6 1 6
(C -C )cycloalkyl, (C -C )cycloalkyl(C -C )alkyl, or phenyl(C -C )alkyl; wherein the
3 6 3 6 1 4 1 4
phenyl moiety of the phenyl(C -C )alkyl is optionally substituted one to three times,
independently, by halogen, (C -C )alkyl, or -CF . In a further embodiment, R is
1 4 3
(C -C )alkyl or (C -C )cycloalkyl(C -C )alkyl. In selected embodiments, R is ethyl,
1 6 3 6 1 2
isobutyl, or sec-butyl. In further selected embodiments, R is cyclopropylmethyl,
cyclobutylmethyl, cyclopentylmethyl, or cyclohexylmethyl. In another selected
embodiment, R is cyclopropylmethyl. In a further embodiment, R is phenyl(C -
C )alkyl; wherein the phenyl moiety is optionally substituted one to two times,
independently, by halogen, (C -C )alkyl, or -CF . In a selected embodiment, R is
1 4 3
phenethyl.
One particular embodiment of the invention is a compound of Formula (I) or a
pharmaceutically acceptable salt thereof wherein:
PU64508
R and R are each independently selected from the group consisting of hydrogen,
(C -C )alkyl, (C -C )cycloalkyl, (C -C )bicycloalkyl, heterocycloalkyl,
1 6 3 7 7 9
(C -C )cycloalkyl(C -C )alkyl, phenyl, heteroaryl, phenyl(C -C )alkyl, and
3 7 1 4 1 4
heteroaryl(C -C )alkyl;
wherein any (C -C )alkyl group is optionally substituted one to three
times, independently, by (C -C )cycloalkyl, -CF , cyano, -CO (C -C )alkyl,
3 6 3 2 1 4
hydroxyl, or (C -C )alkoxy;
and wherein any cycloalkyl, bicycloalkyl, or heterocycloalkyl group is
optionally substituted one to three times, independently, by (C -C )alkyl, -CF ,
1 4 3
cyano, -CO (C -C )alkyl, hydroxyl, (C -C )alkoxy, phenyl, or phenyl(C -C )alkyl;
2 1 4 1 4 1 2
wherein the phenyl moiety of said phenyl or phenyl(C -C )alkyl is optionally
substituted one to three times, independently, by halogen, -CF , (C -C )alkyl,
3 1 4
hydroxyl, or (C -C )alkoxy;
and wherein any phenyl or heteroaryl group is optionally substituted one to
three times, independently, by halogen, (C -C )alkyl, (C -C )cycloalkyl, -CF ,
1 6 3 6 3
cyano, -CO (C -C )alkyl, -SO (C -C )alkyl, hydroxyl, (C -C )alkoxy, phenyl,
2 1 4 2 1 4 1 4
heteroaryl, phenyl(C -C )alkyl, or heteroaryl(C -C )alkyl;
1 2 1 2
wherein any phenyl or heteroaryl moiety of said phenyl, heteroaryl,
phenyl(C -C )alkyl, or heteroaryl(C -C )alkyl is optionally substituted one
1 2 1 2
to three times, independently, by halogen, -CF , or (C -C )alkyl;
3 1 4
and wherein any (C -C )cycloalkyl is optionally substituted one to
three times, independently, by (C -C )alkyl, phenyl, or heteroaryl;
wherein said phenyl or heteroaryl is optionally substituted
one to three times, independently, by halogen, -CF , or
(C -C )alkyl;
or R and R taken together with the nitrogen to which they are attached represent
a 5- to 6-membered saturated or unsaturated ring optionally fused to a phenyl moiety;
or R and R taken together with the nitrogen to which they are attached represent
a 7- to 9-membered bridged bicyclic ring system optionally fused to a phenyl moiety; and
R is (C -C )alkyl or (C -C )cycloalkyl(C -C )alkyl.
1 6 3 6 1 2
Another particular embodiment of the invention is a compound of Formula (I) or a
pharmaceutically acceptable salt thereof wherein:
PU64508
R and R taken together with the nitrogen to which they are attached represent a
- to 6-membered saturated or unsaturated ring optionally fused to a phenyl moiety; and
R is (C -C )alkyl or (C -C )cycloalkyl(C -C )alkyl.
1 6 3 6 1 2
Another particular embodiment of the invention is a compound of Formula (I) or a
pharmaceutically acceptable salt thereof wherein:
R and R taken together with the nitrogen to which they are attached represent
2,3-dihydro-1H-indolyl; and
R is (C -C )alkyl or (C -C )cycloalkyl(C -C )alkyl.
1 6 3 6 1 2
Another particular embodiment of the invention is a compound of Formula (I) or a
pharmaceutically acceptable salt thereof wherein:
R is heteroaryl optionally substituted one to two times, independently, by
halogen, (C -C )alkyl, -CF , cyano, -CO (C -C )alkyl, hydroxyl, or (C -C )alkoxy;
1 4 3 2 1 4 1 4
wherein said heteroaryl is selected from the group consisting of furanyl, thienyl, pyrrolyl,
imidazolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl,
thiadiazolyl, and isothiazolyl; and
R is hydrogen or methyl;
R is (C -C )alkyl or (C -C )cycloalkyl(C -C )alkyl.
1 6 3 6 1 2
Another particular embodiment of the invention is a compound of Formula (I) or a
pharmaceutically acceptable salt thereof wherein:
R is thiadiazolyl optionally substituted by halogen, (C -C )alkyl, -CF ,
1 4 3
(C -C )cycloalkyl, phenyl, cyano, -CO (C -C )alkyl, or (C -C )alkoxy; wherein said
3 6 2 1 4 1 4
(C -C )cycloalkyl is optionally substituted by (C -C )alkyl;
3 6 1 4
R is hydrogen or methyl; and
R is (C -C )alkyl or (C -C )cycloalkyl(C -C )alkyl.
1 6 3 6 1 2
Specific compounds of Formula (I) are:
4-amino-N-[(1S,2E)(2,3-dihydro-1H-indolyl)ethyloxobuten
yl]tetrahydro-2H-pyrancarboxamide; and
4-amino-N-[(1S,2E)(2,3-dihydro-1H-indolyl)(2-methylpropyl)oxo
butenyl]tetrahydro-2H-pyrancarboxamide;
or pharmaceutically acceptable salts thereof.
PU64508
The invention also includes various isomers of the compounds of Formula (I) and
mixtures thereof. “Isomer” refers to compounds that have the same composition and
molecular weight but differ in physical and/or chemical properties. The structural
difference may be in constitution (geometric isomers) or in the ability to rotate the plane
of polarized light (stereoisomers). The compounds according to Formula (I) contain one
or more asymmetric centers, also referred to as chiral centers, and may, therefore, exist as
individual enantiomers, diastereomers, or other stereoisomeric forms, or as mixtures
thereof. All such isomeric forms are included within the present invention, including
mixtures thereof.
Chiral centers may also be present in a substituent such as an alkyl group. Where
the stereochemistry of a chiral center present in Formula (I), or in any chemical structure
illustrated herein, is not specified the structure is intended to encompass any stereoisomer
and all mixtures thereof. Thus, compounds according to Formula (I) containing one or
more chiral centers may be used as racemic mixtures, enantiomerically enriched mixtures,
or as enantiomerically pure individual stereoisomers.
Individual stereoisomers of a compound according to Formula (I) which contain
one or more asymmetric centers may be resolved by methods known to those skilled in
the art. For example, such resolution may be carried out (1) by formation of
diastereoisomeric salts, complexes or other derivatives; (2) by selective reaction with a
stereoisomer-specific reagent, for example by enzymatic oxidation or reduction; or (3) by
gas-liquid or liquid chromatography in a chiral environment, for example, on a chiral
support such as silica with a bound chiral ligand or in the presence of a chiral solvent.
The skilled artisan will appreciate that where the desired stereoisomer is converted into
another chemical entity by one of the separation procedures described above, a further
step is required to liberate the desired form. Alternatively, specific stereoisomers may be
synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts
or solvents, or by converting one enantiomer to the other by asymmetric transformation.
The invention also includes various deuterated forms of the compounds of
Formula (I). Each available hydrogen atom attached to a carbon atom may be
independently replaced with a deuterium atom. A person of ordinary skill in the art will
know how to synthesize deuterated forms of the compounds of Formula (I). For example,
α-deuterated α-amino acids are commercially available or may be prepared by
PU64508
conventional techniques (see for example: Elemes, Y. and Ragnarsson, U. J. Chem. Soc.,
Perkin Trans. 1, 1996, 6, 537-40). Employing such compounds according to Scheme 1
below will allow for the preparation of compounds of Formula (I) in which the hydrogen
atom at the chiral center is replaced with a deuterium atom. Similarly, α-amino acids in
which deuterium atoms have been incorporated into the sidechains are commercially
available or may be prepared by conventional techniques. Employing such compounds
according to Scheme 1 below will allow for the preparation of compounds of Formula (I)
in which deuterium atoms have been incorporated in R . Additionally, replacement of the
reagent lithium aluminum hydride with lithium aluminum deuteride according to Scheme
1 below will allow for deuterium substitution at the β-position of the butenamide of the
compounds of Formula (I).
The term “solvate” refers to a complex of variable stoichiometry formed by a
solute and a solvent. Such solvents for the purpose of the invention may not interfere
with the biological activity of the solute. Examples of suitable solvents include, but are
not limited to, water, methanol, ethanol and acetic acid. Preferably, the solvent used is a
pharmaceutically acceptable solvent. Examples of suitable pharmaceutically acceptable
solvents include, without limitation, water, ethanol and acetic acid. Solvates wherein
water is the solvent molecule are typically referred to as “hydrates”. Hydrates include
compositions containing stoichiometric amounts of water, as well as compositions
containing variable amounts of water. Solvates, particularly hydrates, of the compounds
of Formula (I) and salts thereof, are within the scope of the invention.
When a disclosed compound or its salt is named or depicted by structure, it is to
be understood that the compound or salt, including solvates (particularly, hydrates)
thereof, may exist in crystalline forms, non-crystalline forms or a mixture thereof. The
compound or salt, or solvates (particularly, hydrates) thereof, may also exhibit
polymorphism (i.e. the capacity to occur in different crystalline forms). These different
crystalline forms are typically known as “polymorphs.” It is to be understood that when
named or depicted by structure, the disclosed compound, or solvates (particularly,
hydrates) thereof, also include all polymorphs thereof. Polymorphs have the same
chemical composition but differ in packing, geometrical arrangement, and other
descriptive properties of the crystalline solid state. Polymorphs, therefore, may have
different physical properties such as shape, density, hardness, deformability, stability, and
PU64508
dissolution properties. Polymorphs typically exhibit different melting points, IR spectra,
and X-ray powder diffraction patterns, which may be used for identification. One of
ordinary skill in the art will appreciate that different polymorphs may be produced, for
example, by changing or adjusting the conditions used in crystallizing/recrystallizing the
compound.
Because of their potential use in medicine, the salts of the compounds of Formula
(I) are preferably pharmaceutically acceptable. Suitable pharmaceutically acceptable salts
can include acid or base addition salts. This invention also provides for the conversion of
one pharmaceutically acceptable salt of a compound of this invention, e.g., a
hydrochloride salt, into another pharmaceutically acceptable salt of a compound of this
invention, e.g., a sulfate salt.
As used herein, the term “pharmaceutically acceptable” means a compound which
is suitable for pharmaceutical use. Salts and solvates (e.g. hydrates and hydrates of salts)
of the compounds of the invention which are suitable for use in medicine are those
wherein the counterion or associated solvent is pharmaceutically acceptable. However,
salts and solvates having non-pharmaceutically acceptable counterions or associated
solvents are within the scope of the present invention, for example, for use as
intermediates in the preparation of other compounds of the invention and their salts and
solvates.
Compounds of Formula (I) have one or more nitrogen(s) basic enough to form
pharmaceutically acceptable acid addition salts by treatment with a suitable acid.
Suitable acids include pharmaceutically acceptable inorganic acids and pharmaceutically
acceptable organic acids. Representative pharmaceutically acceptable acid addition salts
include acetate, aspartate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide,
calcium edetate, camsylate, carbonate, chloride, citrate, dihydrochloride, edetate,
edisylate, estolate, esylate, formate, fumarate, galacturonate, gluceptate, gluconate,
glutamate, glycollylarsanilate, hexanoate, hydrobromide, hydrochloride,
hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, mandelate,
mesylate, methylsulfate, mucate, napsylate, nitrate, pamoate, pantothenate,
phosphate/diphosphate, polygalacturonate, propionate, salicylate, stearate, subacetate,
succinate, sulfate, tannate, tartrate, teoclate, and tosylate salts.
PU64508
Other iterations of compounds of the invention have an acidic functional group,
one acidic enough to form salts. Representative salts include pharmaceutically acceptable
metal salts such as sodium, potassium, lithium, calcium, magnesium, aluminum, and zinc
salts; carbonates and bicarbonates of a pharmaceutically acceptable metal cation such as
sodium, potassium, lithium, calcium, magnesium, aluminum, and zinc; pharmaceutically
acceptable organic primary, secondary, and tertiary amines including aliphatic amines,
aromatic amines, aliphatic diamines, and hydroxy alkylamines such as methylamine,
ethylamine, 2-hydroxyethylamine, diethylamine, triethylamine, ethylenediamine,
ethanolamine, diethanolamine, cyclohexylamine, triethanolamine, choline, arginine,
lysine, and histidine.
Other non-pharmaceutically acceptable salts, e.g. trifluoroacetate, may be used,
for example in the isolation of compounds of the invention, and are included within the
scope of this invention.
The invention includes within its scope all possible stoichiometric and non-
stoichiometric forms of the salts of the compounds of Formula (I).
It will be appreciated by those skilled in the art that certain protected derivatives of
compounds of Formula (I), which may be made prior to a final deprotection stage, may not
possess pharmacological activity as such, but may, in certain instances, be administered
orally or parenterally and thereafter metabolized in the body to form compounds of the
invention which are pharmacologically active. Such derivatives may therefore be described
as “prodrugs”. Further, certain compounds of the invention may act as prodrugs of other
compounds of the invention. All protected derivatives and prodrugs of compounds of the
invention are included within the scope of the invention. Examples of suitable pro-drugs for
the compounds of the present invention are described in Drugs of Today, Volume 19,
Number 9, 1983, pp 499 – 538 and in Topics in Chemistry, Chapter 31, pp 306 – 316 and in
“Design of Prodrugs” by H. Bundgaard, Elsevier, 1985, Chapter 1 (the disclosures in which
documents are incorporated herein by reference). It will further be appreciated by those
skilled in the art, that certain moieties, known to those skilled in the art as “pro-moieties”, for
example as described by H. Bundgaard in “Design of Prodrugs” (the disclosure in which
document is incorporated herein by reference) may be placed on appropriate functionalities
when such functionalities are present within compounds of the invention. Preferred “pro-
moieties” for compounds of the invention include: ester, carbonate ester, hemi-ester,
PU64508
phosphate ester, nitro ester, sulfate ester, sulfoxide, amide, carbamate, azo-, phosphamide,
glycoside, ether, acetal, and ketal derivatives of the compounds of Formula (I).
The compounds of the invention inhibit the cathepsin C enzyme and can be useful
in the treatment of conditions wherein the underlying pathology is (at least in part)
attributable to cathepsin C involvement or in conditions wherein cathepsin C inhibition
offers some clinical benefit even though the underlying pathology is not (even in part)
attributable to cathepsin C involvement. Examples of such conditions include COPD,
rheumatoid arthritis, osteoarthritis, asthma, and multiple sclerosis. Accordingly,
described herein are methods of treating such conditions.
The methods of treatment described herein comprise administering an effective
amount of a compound of the invention to a patient in need thereof.
As used herein, "treatment" in reference to a condition means: (1) the amelioration
of the condition being treated or one or more of the biological manifestations of the
condition being treated, (2) the interference with (a) one or more points in the biological
cascade that leads to or is responsible for the condition being treated or (b) one or more of
the biological manifestations of the condition being treated, or (3) the alleviation of one
or more of the symptoms or effects associated with the condition being treated.
An "effective amount" means that amount of a drug or pharmaceutical agent that
will elicit the biological or medical response of a tissue, system, animal or human that is
being sought, for instance, by a researcher or clinician. Furthermore, the term
“therapeutically effective amount” means any amount which, as compared to a
corresponding subject who has not received such amount, results in improved treatment,
healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in
the rate of advancement of a disease or disorder. The term also includes within its scope
amounts effective to enhance normal physiological function.
As used herein, "patient" refers to a human or animal.
The compounds of the invention may be administered by any suitable route of
administration, including both systemic administration and topical administration.
Systemic administration includes oral administration, parenteral administration,
transdermal administration, rectal administration, and administration by inhalation.
Parenteral administration refers to routes of administration other than enteral,
transdermal, or by inhalation, and is typically by injection or infusion. Parenteral
PU64508
administration includes intravenous, intramuscular, and subcutaneous injection or
infusion. Inhalation refers to administration into the patient's lungs whether inhaled
through the mouth or through the nasal passages. Topical administration includes
application to the skin as well as intraocular, otic, intravaginal, and intranasal
administration.
The compounds of the invention may be administered once or according to a
dosing regimen wherein a number of doses are administered at varying intervals of time
for a given period of time. For example, doses may be administered one, two, three, or
four times per day. Doses may be administered until the desired therapeutic effect is
achieved or indefinitely to maintain the desired therapeutic effect. Suitable dosing
regimens for a compound of the invention depend on the pharmacokinetic properties of
that compound, such as absorption, distribution, and half-life, which can be determined
by the skilled artisan. In addition, suitable dosing regimens, including the amount
administered and the duration such regimens are administered, for a compound of the
invention depend on the condition being treated, the severity of the condition being
treated, the age and physical condition of the patient being treated, the medical history of
the patient to be treated, the nature of concurrent therapy, the particular route of
administration chosen, the desired therapeutic effect, and like factors within the
knowledge and expertise of the skilled artisan. It will be further understood by such
skilled artisans that suitable dosing regimens may require adjustment given an individual
patient's response to the dosing regimen or over time as individual patient needs change.
Typical daily dosages range from 1 mg to 1000 mg.
The invention includes the use of compounds of the invention for the preparation
of a composition for treating or ameliorating diseases mediated by the cathepsin C
enzyme in a subject in need thereof, wherein the composition comprises a mixture of one
or more of the compounds of the invention and an optional pharmaceutically acceptable
excipient.
Also described herein is the use of compounds of the invention as an active
therapeutic substance, in particular in the treatment of diseases mediated by the cathepsin
C enzyme. Specifically, described herein is the use of compounds of the invention in the
treatment of COPD, rheumatoid arthritis, osteoarthritis, asthma, and multiple sclerosis.
PU64508
In another aspect, the invention includes the use of compounds of the invention in
the manufacture of a medicament for use in the treatment of the above disorders.
Compositions
The compounds of the invention will normally, but not necessarily, be formulated
into a pharmaceutical composition prior to administration to a patient. Accordingly, in
another aspect the invention is directed to pharmaceutical compositions comprising a
compound of the invention and a pharmaceutically acceptable excipient.
The pharmaceutical compositions of the invention may be prepared and packaged
in bulk form wherein an effective amount of a compound of the invention can be
extracted and then given to the patient such as with powders, syrups, and solutions for
injection. Alternatively, the pharmaceutical compositions of the invention may be
prepared and packaged in unit dosage form wherein each physically discrete unit contains
an effective amount of a compound of the invention. When prepared in unit dosage form,
the pharmaceutical compositions of the invention typically contain from 1 mg to 1000
The pharmaceutical compositions of the invention typically contain one
compound of the invention. However, in certain embodiments, the pharmaceutical
compositions of the invention contain more than one compound of the invention. For
example, in certain embodiments the pharmaceutical compositions of the invention
contain two compounds of the invention. In addition, the pharmaceutical compositions of
the invention may optionally further comprise one or more additional pharmaceutically
active compounds. Conversely, the pharmaceutical compositions of the invention
typically contain more than one pharmaceutically acceptable excipient. However, in
certain embodiments, the pharmaceutical compositions of the invention contain one
pharmaceutically acceptable excipient.
As used herein, "pharmaceutically acceptable excipient" means a material,
composition or vehicle involved in giving form or consistency to the composition and
which is safe when administered to a patient. Each excipient must be compatible with the
other ingredients of the pharmaceutical composition when commingled such that
interactions which would substantially reduce the efficacy of the compound of the
invention when administered to a patient and interactions which would result in
PU64508
pharmaceutical compositions that are not pharmaceutically acceptable are avoided. In
addition, each excipient must of course be of sufficiently high purity to render it
pharmaceutically-acceptable.
The compounds of the invention and the pharmaceutically acceptable excipient or
excipients will typically be formulated into a dosage form adapted for administration to
the patient by the desired route of administration. For example, dosage forms include
those adapted for (1) oral administration such as tablets, capsules, caplets, pills, troches,
powders, syrups, elixirs, suspensions, solutions, emulsions, sachets, and cachets; (2)
parenteral administration such as sterile solutions, suspensions, and powders for
reconstitution; (3) transdermal administration such as transdermal patches; (4) rectal
administration such as suppositories; (5) inhalation such as aerosols and solutions; and (6)
topical administration such as creams, ointments, lotions, solutions, pastes, sprays, foams,
and gels.
Suitable pharmaceutically acceptable excipients will vary depending upon the
particular dosage form chosen. In addition, suitable pharmaceutically acceptable
excipients may be chosen for a particular function that they may serve in the composition.
For example, certain pharmaceutically acceptable excipients may be chosen for their
ability to facilitate the production of uniform dosage forms. Certain pharmaceutically
acceptable excipients may be chosen for their ability to facilitate the production of stable
dosage forms. Certain pharmaceutically acceptable excipients may be chosen for their
ability to facilitate the carrying or transporting the compound or compounds of the
invention once administered to the patient from one organ, or portion of the body, to
another organ, or portion of the body. Certain pharmaceutically acceptable excipients
may be chosen for their ability to enhance patient compliance.
Suitable pharmaceutically acceptable excipients include the following types of
excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents,
coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers,
sweeteners, flavoring agents, flavor masking agents, coloring agents, anti-caking agents,
humectants, chelating agents, plasticizers, viscosity increasing agents, antioxidants,
preservatives, stabilizers, surfactants, and buffering agents. The skilled artisan will
appreciate that certain pharmaceutically acceptable excipients may serve more than one
PU64508
function and may serve alternative functions depending on how much of the excipient is
present in the formulation and what other ingredients are present in the formulation.
Skilled artisans possess the knowledge and skill in the art to enable them to select
suitable pharmaceutically acceptable excipients in appropriate amounts for use in the
invention. In addition, there are a number of resources that are available to the skilled
artisan which describe pharmaceutically acceptable excipients and may be useful in
selecting suitable pharmaceutically acceptable excipients. Examples include Remington's
Pharmaceutical Sciences (Mack Publishing Company), The Handbook of Pharmaceutical
Additives (Gower Publishing Limited), and The Handbook of Pharmaceutical Excipients
(the American Pharmaceutical Association and the Pharmaceutical Press).
The pharmaceutical compositions of the invention are prepared using techniques
and methods known to those skilled in the art. Some of the methods commonly used in
the art are described in Remington's Pharmaceutical Sciences (Mack Publishing
Company).
In one aspect, the invention is directed to a solid oral dosage form such as a tablet
or capsule comprising an effective amount of a compound of the invention and a diluent
or filler. Suitable diluents and fillers include lactose, sucrose, dextrose, mannitol,
sorbitol, starch (e.g. corn starch, potato starch, and pre-gelatinized starch), cellulose and
its derivatives (e.g. microcrystalline cellulose), calcium sulfate, and dibasic calcium
phosphate. The oral solid dosage form may further comprise a binder. Suitable binders
include starch (e.g. corn starch, potato starch, and pre-gelatinized starch), gelatin, acacia,
sodium alginate, alginic acid, tragacanth, guar gum, povidone, and cellulose and its
derivatives (e.g. microcrystalline cellulose). The oral solid dosage form may further
comprise a disintegrant. Suitable disintegrants include crospovidone, sodium starch
glycolate, croscarmelose, alginic acid, and sodium carboxymethyl cellulose. The oral
solid dosage form may further comprise a lubricant. Suitable lubricants include stearic
acid, magnesium stearate, calcium stearate, and talc.
In another aspect, the invention is directed to a dosage form adapted for
administration to a patient by inhalation. For example, the compound of the invention
may be inhaled into the lungs as a dry powder, an aerosol, a suspension, or a solution.
Dry powder compositions for delivery to the lung by inhalation typically comprise
a compound of the invention as a finely divided powder together with one or more
PU64508
pharmaceutically acceptable excipients as finely divided powders. Pharmaceutically
acceptable excipients particularly suited for use in dry powders are known to those skilled
in the art and include lactose, starch, mannitol, and mono-, di-, and polysaccharides.
The dry powder may be administered to the patient via a reservoir dry powder
inhaler (RDPI) having a reservoir suitable for storing multiple (un-metered doses) of
medicament in dry powder form. RDPIs typically include a means for metering each
medicament dose from the reservoir to a delivery position. For example, the metering
means may comprise a metering cup, which is movable from a first position where the
cup may be filled with medicament from the reservoir to a second position where the
metered medicament dose is made available to the patient for inhalation.
Alternatively, the dry powder may be presented in capsules (e.g. gelatin or
plastic), cartridges, or blister packs for use in a multi-dose dry powder inhaler (MDPI).
MDPIs are inhalers wherein the medicament is comprised within a multi-dose pack
containing (or otherwise carrying) multiple defined doses (or parts thereof) of
medicament. When the dry powder is presented as a blister pack, it comprises multiple
blisters for containment of the medicament in dry powder form. The blisters are typically
arranged in regular fashion for ease of release of the medicament therefrom. For
example, the blisters may be arranged in a generally circular fashion on a disc-form
blister pack, or the blisters may be elongate in form, for example comprising a strip or a
tape. Each capsule, cartridge, or blister may, for example, contain between 20μg-10mg of
the compound of the invention.
Aerosols may be formed by suspending or dissolving a compound of the invention
in a liquified propellant. Suitable propellants include halocarbons, hydrocarbons, and
other liquified gases. Representative propellants include: trichlorofluoromethane
(propellant 11), dichlorofluoromethane (propellant 12), dichlorotetrafluoroethane
(propellant 114), tetrafluoroethane (HFA-134a), 1,1-difluoroethane (HFA-152a),
difluoromethane (HFA-32), pentafluoroethane (HFA-12), heptafluoropropane (HFA-
227a), perfluoropropane, perfluorobutane, perfluoropentane, butane, isobutane, and
pentane. Aerosols comprising a compound of the invention will typically be administered
to a patient via a metered dose inhaler (MDI). Such devices are known to those skilled in
the art.
PU64508
The aerosol may contain additional pharmaceutically acceptable excipients
typically used with multiple dose inhalers such as surfactants, lubricants, cosolvents and
other excipients to improve the physical stability of the formulation, to improve valve
performance, to improve solubility, or to improve taste.
Suspensions and solutions comprising a compound of the invention may also be
administered to a patient via a nebulizer. The solvent or suspension agent utilized for
nebulization may be any pharmaceutically acceptable liquid such as water, aqueous
saline, alcohols or glycols, e.g., ethanol, isopropylalcohol, glycerol, propylene glycol,
polyethylene glycol, etc. or mixtures thereof. Saline solutions utilize salts which display
little or no pharmacological activity after administration. Both organic salts, such as
alkali metal or ammonium halogen salts, e.g., sodium chloride, potassium chloride or
organic salts, such as potassium, sodium and ammonium salts or organic acids, e.g.,
ascorbic acid, citric acid, acetic acid, tartaric acid, etc. may be used for this purpose.
Other pharmaceutically acceptable excipients may be added to the suspension or
solution. The compound of the invention may be stabilized by the addition of an
inorganic acid, e.g., hydrochloric acid, nitric acid, sulfuric acid and/or phosphoric acid; an
organic acid, e.g., ascorbic acid, citric acid, acetic acid, and tartaric acid, etc., a
complexing agent such as EDTA or citric acid and salts thereof; or an antioxidant such as
antioxidant such as vitamin E or ascorbic acid. These may be used alone or together to
stabilize the compound of the invention. Preservatives may be added such as
benzalkonium chloride or benzoic acid and salts thereof. Surfactant may be added
particularly to improve the physical stability of suspensions. These include lecithin,
disodium dioctylsulphosuccinate, oleic acid and sorbitan esters.
Methods of Preparation.
The compounds of Formula (I) may be obtained by using synthetic procedures
illustrated in the Schemes below or by drawing on the knowledge of a skilled organic
chemist. The synthesis provided in these Schemes are applicable for producing
compounds of the invention having a variety of different R -R groups employing
appropriate precursors, which are suitably protected if need be, to achieve compatibility
with the reactions outlined herein. Subsequent deprotection, where needs be, and then
affords compounds of the nature generally disclosed. While the Schemes are shown with
PU64508
compounds only of Formula (I), they are illustrative of processes that may be used to
make the compounds of the invention.
Compounds names were generated using the software naming program
ACD/Name Pro V6.02 available from Advanced Chemistry Development, Inc., 110
Yonge Street, 14 Floor, Toronto, Ontario, Canada, M5C 1T4 (http://www.acdlabs.com/).
As shown in Scheme 1, the compounds of Formula (I) can be prepared in a multi-
step sequence starting from a Boc-protected α-amino acid, such as the commercially
available (2S)({[(1,1-dimethylethyl)oxy]carbonyl}amino)butanoic acid or N-(tert-
butoxycarbonyl)-L-leucine. Formation of an appropriate amide derivative, such as a
Weinreb amide, using an appropriate amine or amine salt, such as
N,O-dimethylhydroxylamine hydrochloride, with an appropriate coupling reagent, such as
1,1′-carbonyldiimidazole, and an appropriate base, such as DIPEA, in an appropriate
solvent, such as CH Cl , followed by reduction with an appropriate reducing agent, such
as LiAlH , in an appropriate solvent, such as Et O, provides the requisite aldehyde.
Enoate formation with an appropriate olefinating reagent, such as methyl
(triphenylphosphoranylidene) acetate, in an appropriate solvent, such as Et O, is followed
by ester hydrolysis with an appropriate reagent, such as LiOH, in an appropriate solvent
system, such as THF, MeOH, and water. This is followed by amide bond formation with
an appropriate acyclic or cyclic amine and an appropriate coupling reagent or reagents,
such as T3P or the BOP reagent, and an appropriate base, such as Et N or DIPEA, in an
appropriate solvent, such as CH Cl or DMF. Boc deprotection with an appropriate
reagent, such as TFA, is followed by coupling of the liberated amine with 4-((tert-
butoxycarbonyl)amino)tetrahydro-2H-pyrancarboxylic acid, with an appropriate
coupling reagent or reagents, such as T3P, and an appropriate base, such as Et N, in an
appropriate solvent, such as CH Cl . Boc deprotection with an appropriate reagent, such
as HCl, results in the formation of the desired compounds of Formula (I), which may be
isolated as the corresponding salt form or converted to the free base using conventional
techniques.
PU64508
Scheme 1
Reagents and conditions: a) HCl•HN(OCH )CH , DIPEA, 1,1′-carbonyldiimidazole,
CH Cl ; b) LiAlH , Et O; c) Ph P=CHCO CH , Et O; d) LiOH, THF, MeOH, water; e)
2 2 4 2 3 2 3 2
1 2 ® 1 2
HNR R , T3P, EtOAc, Et N, CH Cl or HNR R , BOP reagent, DIPEA, DMF ; f) TFA,
3 2 2
CH Cl ; g) 4-((tert-butoxycarbonyl)amino)tetrahydro-2H-pyrancarboxylic acid, T3P,
EtOAc, Et N, CH Cl ; h) HCl, isopropanol.
3 2 2
SYNTHETIC EXAMPLES
The invention will now be described by reference to the following examples
which are merely illustrative and are not to be construed as a limitation of the scope of the
present invention. All temperatures are given in degrees Celsius, all solvents are highest
available purity and all reactions run under anhydrous conditions in an argon (Ar) or
nitrogen (N ) atmosphere where necessary.
Analtech Silica Gel GF and E. Merck Silica Gel 60 F-254 thin layer plates were
used for thin layer chromatography. Both flash and gravity chromatography were carried
out on E. Merck Kieselgel 60 (230-400 mesh) silica gel. The CombiFlash system used
for purification in this application was purchased from Isco, Inc. CombiFlash
purification was carried out using prepacked silica gel columns, a detector with UV
wavelength at 254 nm and a variety of solvents or solvent combinations. Preparative
PU64508
HPLC was performed using a Gilson Preparative System with variable wavelength UV
detection or an Agilent Mass Directed AutoPrep (MDAP) system with both mass and
variable wavelength UV detection. A variety of reverse phase columns, e.g., Luna 5u
C18(2) 100A, SunFire C18, XBridge C18 were used in the purification with the choice of
column support dependent upon the conditions used in the purification. The compounds
are eluted using a gradient of CH CN and water. Neutral conditions used an CH CN and
water gradient with no additional modifier, acidic conditions used an acid modifier,
usually 0.1% TFA (added to both the CH CN and water) and basic conditions used a
basic modifier, usually 0.1% NH OH (added to the water). Analytical HPLC was run
using an Agilent system with variable wavelength UV detection using reverse phase
chromatography with an CH CN and water gradient with a 0.05 or 0.1% TFA modifier
(added to each solvent). LC-MS was determined using either a PE Sciex Single
Quadrupole LC/MS API-150a, or Waters ZQ instruments. The compound is analyzed
using a reverse phase column, e.g., Thermo Aquasil/Aquasil C18, Acquity UPLC C18,
Thermo Hypersil Gold eluted using an CH CN and water gradient with a low percentage
of an acid modifier such as 0.02% TFA or 0.1% formic acid.
Nuclear magnetic resonance spectra were recorded at 400 MHz using a Bruker
AVANCE 400 or Brucker DPX400 spectrometer. CDCl is deuteriochloroform,
DMSO-d is hexadeuteriodimethylsulfoxide, and MeOD is tetradeuteriomethanol.
Chemical shifts are reported in parts per million (δ) downfield from the internal standard
tetramethylsilane (TMS) or calibrated to the residual proton signal in the NMR solvent
(e.g., CHCl in CDCl ). Abbreviations for NMR data are as follows: s = singlet, d =
doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets, dt = doublet of
triplets, app = apparent, br = broad. J indicates the NMR coupling constant measured in
Hertz. Melting points were determined using an Electrothermal 9100 apparatus
(Electrothermal Engineering Ltd.).
Heating of reaction mixtures with microwave irradiations was carried out on a
Smith Creator (purchased from Personal Chemistry, Foxboro, MA, now owned by
Biotage), an Emrys Optimizer (purchased from Personal Chemistry) or an Explorer
(purchased from CEM, Matthews, NC) microwave.
Cartridges or columns containing polymer based functional groups (acid, base,
metal chelators, etc) can be used as part of compound workup. The "amine" columns or
PU64508
cartridges are used to neutralize or basify acidic reaction mixtures or products. These
include NH2 Aminopropyl SPE-ed SPE Cartridges available from Applied Separations
and diethylamino SPE cartridges available from United Chemical Technologies, Inc.
Abbreviations are listed in the table below. All other abbreviations are as
described in the ACS Style Guide (American Chemical Society, Washington, DC, 1986).
Table of Abbreviations
BOP reagent: benzotriazoleyl-oxy-tris-
T3P: propane phosphonic acid
(dimethylamino)-phosphonium
anhydride
hexafluorophosphate
Et N: triethylamine CH Cl : dichloromethane
3 2 2
DIPEA: N,N-diisopropylethylamine DMSO: dimethyl sulfoxide
TFA: trifluoroacetic acid THF: tetrahydrofuran
HCl: hydrochloric acid DMF: N,N-dimethylformamide
NaHCO : sodium bicarbonate EtOAc: ethyl acetate
Na SO : sodium sulfate Et O: diethyl ether
2 4 2
LiAlH : lithium aluminum hydride MeOH: methanol
mL: milliliter(s) CH CN: acetonitrile
min: minute(s) aq.: aqueous
h: hour(s) M: molar
g: gram(s) mmol: millimole(s)
mg: milligram(s) RT: room temperature
PU64508
INTERMEDIATE COMPOUNDS
Intermediate 1
1,1-dimethylethyl ((1S){[methyl(methyloxy)amino]carbonyl}propyl)carbamate
O N O
To a solution of (2S)({[(1,1-dimethylethyl)oxy]carbonyl}amino)butanoic acid
(2.50 g, 12.3 mmol) in THF (15.0 mL) was added 1,1′-carbonyldiimidazole (2.39 g, 14.8
mmol) portionwise over about 10 min. After stirring 30 min at RT, a solution of N,O-
dimethylhydroxylamine hydrochloride (1.32 g, 13.5 mmol) and DIPEA (2.36 mL, 13.5
mmol) in DMF (4.0 mL) was added. The reaction mixture was stirred for 2 h at RT, followed
by concentration in vacuo. The residue was diluted with EtOAc (50 mL) and washed with 1
M aq. HCl (2 x 20 mL), saturated aq. NaHCO (2 x 20 mL), and brine (20 mL). The organic
layer was dried over Na SO , filtered, and concentrated in vacuo to afford the title compound
(2.60 g, 88%) as a clear, colorless oil. LC-MS m/z 247 (M+H) , 0.94 min (ret time).
Intermediate 2
1,1-dimethylethyl [(1S)formylpropyl]carbamate
O N O O N
To a solution of LiAlH (0.453 g, 11.9 mmol) in Et O (20 mL) at 0 °C was added
dropwise a solution of 1,1-dimethylethyl ((1S){[methyl(methyloxy)amino]carbonyl}-
propyl)carbamate (2.67 g, 10.8 mmol) in Et O (15 mL). The reaction mixture was stirred for
30 min at 0 °C and quenched with EtOAc (6.5 mL) followed by 5% aq. potassium bisulfate
(6.5 mL). The reaction mixture was washed with 1 M aq. HCl (3 x 10 mL), saturated aq.
NaHCO (3 x 10 mL), and brine (10 mL). The organic layer was dried over Na SO , filtered,
3 2 4
and concentrated in vacuo to afford the title compound as a clear, colorless oil.
PU64508
Intermediate 3
methyl (2E,4S)({[(1,1-dimethylethyl)oxy]carbonyl}amino)hexenoate
O N O N
To a stirred solution of methyl (triphenylphosphoranylidene) acetate (4.35 g, 13.0
mmol) in Et O (25 mL) at RT was added a solution of Intermediate 2 in Et O (15 mL). The
reaction mixture was stirred at RT overnight. The solid was removed by filtration and the
solution was concentrated in vacuo. Purification via flash column chromatography (0-50%
EtOAc/hexanes) afforded the title compound (1.44 g, 55% over two steps) as a clear,
colorless oil. LC-MS m/z 244 (M+H) , 0.98 min (ret time).
Intermediate 4
(2E,4S)({[(1,1-dimethylethyl)oxy]carbonyl}amino)hexenoic acid
O N O N
O OH
LiOH (2.95 g, 123 mmol) was added to a solution of methyl (2E,4S)({[(1,1-
dimethylethyl)oxy]carbonyl}amino)hexenoate (6 g, 24.66 mmol) in THF (50 mL),
MeOH (10.00 mL), and water (50.0 mL). The reaction was stirred overnight at RT.
After 18.5 h, the reaction mixture was concentrated under reduced pressure to remove the
THF and MeOH. Water (40 mL) was added, and aqueous mixture was adjusted to pH = 3
with 6 M aq. HCl, as measured by pH paper. EtOAc (80 mL) was added, the layers were
separated, and the aqueous layer was extracted with EtOAc (2 x 40 mL). The combined
organic layers were dried over Na SO , concentrated under reduced pressure, and dried
under high vacuum, giving 6.09 g of the title compound. LC-MS m/z 230 (M+H) , 0.77
min (ret time).
PU64508
Intermediate 5
1,1-dimethylethyl [(1S,2E)(2,3-dihydro-1H-indolyl)ethyloxobuten
yl]carbamate
O N O N
OH HN N
A solution of 50 wt% T3P in EtOAc (22.00 mL, 37.0 mmol) was added dropwise
via addition funnel to a solution of (2E,4S)({[(1,1-dimethylethyl)oxy]carbonyl}-
amino)hexenoic acid (5.65 g, 24.64 mmol), 2,3-dihydro-1H-indole (2.76 mL, 24.64
mmol), and Et N (11 mL, 79 mmol) in CH Cl (90 mL) at 0 ºC (bath temp). The ice bath
3 2 2
was removed, and the reaction was stirred at RT. After 30 min, the reaction was
quenched by dropwise addition of saturated aq. NaHCO (50 mL). The layers were
separated, and the reaction was washed with 10% citric acid (1 x 50 mL). The organic
layer was concentrated under a stream of nitrogen, and the residue was purified by flash
column chromatography, giving 7.21 g (89%) of the title compound. LC-MS m/z 331
(M+H) , 1.05 (ret time).
Intermediate 6
[(1S,2E)(2,3-dihydro-1H-indolyl)ethyloxobutenyl]amine
trifluoroacetate
O N H N
TFA (25 mL, 324 mmol) was added to a solution of 1,1-dimethylethyl [(1S,2E)
(2,3-dihydro-1H-indolyl)ethyloxobutenyl]carbamate (7.21 g, 21.82 mmol)
in CH Cl (25 mL). The reaction was stirred at RT. After 3.5 h, CH Cl (200 mL) was
2 2 2 2
added, and the reaction was concentrated under reduced pressure and dried under high
vacuum. LC-MS m/z 231 (M+H) , 0.69 (ret time).
PU64508
Intermediate 7
1,1-dimethylethyl [4-({[(1S,2E)(2,3-dihydro-1H-indolyl)ethyloxobuten-
1-yl]amino}carbonyl)tetrahydro-2H-pyranyl]carbamate
O O O
OH HN N
N N O N N
A solution of 50 wt% T3P in EtOAc (1.3 mL, 2.184 mmol) was added dropwise
to a solution of [(1S,2E)(2,3-dihydro-1H-indolyl)ethyloxobutenyl]amine
trifluoroacetate (500 mg, 1.452 mmol), 4-((tert-butoxycarbonyl)amino)tetrahydro-2H-
pyrancarboxylic acid (356 mg, 1.452 mmol), and Et N (1 mL, 7.21 mmol) in CH Cl
3 2 2
(5 mL) at 0 ºC (bath temp). The ice bath was removed, and the reaction was stirred at
RT. After 1 h 20 min, the reaction mixture was washed with saturated aq. NaHCO (1 x 5
mL) and 10% citric acid (1 x 5 mL). The organic layer was concentrated under a stream
of nitrogen, and the residue was purified by flash column chromatography, giving 251 mg
(38%) of the title compound. LC-MS m/z 458 (M+H) , 0.96 (ret time).
Intermediate 8
2 1 1
N -{[(1,1-dimethylethyl)oxy]carbonyl}-N -methyl-N -(methyloxy)-L-leucinamide
O N O
To a solution of N-(tert-butoxycarbonyl)-L-leucine (3.00 g, 13.0 mmol) in THF (25.0
mL) was added 1,1′-carbonyldiimidazole (2.52 g, 15.6 mmol) portionwise over about 10 min.
After stirring 1 h at RT, a solution of N,O-dimethylhydroxylamine hydrochloride (1.39 g,
14.3 mmol) and DIPEA (2.49 mL, 14.3 mmol) in DMF (6.0 mL) was added. The reaction
mixture was stirred for 2.5 h at RT, followed by concentration in vacuo. The residue was
diluted with EtOAc (50 mL) and washed with 1 M aq. HCl (2 x 20 mL), saturated aq.
NaHCO (2 x 20 mL), and brine (20 mL). The organic layer was dried over Na SO , filtered,
3 2 4
and concentrated in vacuo to afford the title compound (2.34 g, 66%) as a clear, colorless oil.
LC-MS m/z 275 (M+H) , 1.17 min (ret time).
PU64508
Intermediate 9
1,1-dimethylethyl [(1S)formylmethylbutyl]carbamate
O N O O N
To a solution of LiAlH (0.356 g, 9.38 mmol) in Et O (20 mL) at 0 °C was added
2 1 1
dropwise a solution of N -{[(1,1-dimethylethyl)oxy]carbonyl}-N -methyl-N -(methyloxy)-L-
leucinamide (2.34 g, 8.53 mmol) in Et O (15 mL). The reaction mixture was stirred for 30
min at 0 °C and quenched with EtOAc (6 mL) followed by 5% aq. potassium bisulfate (6
mL). The reaction mixture was washed with 1 M aq. HCl (2 x 10 mL), saturated aq.
NaHCO (2 x 10 mL), and brine (10 mL). The organic layer was dried over Na SO , filtered,
3 2 4
and concentrated in vacuo to afford the title compound as a clear, colorless oil.
Intermediate 10
methyl (2E,4S)({[(1,1-dimethylethyl)oxy]carbonyl}amino)methylheptenoate
O N O N
To a stirred solution of methyl (triphenylphosphoranylidene) acetate (3.42 g, 10.2
mmol) in Et O (25 mL) at RT was added a solution of Intermediate 9 in Et O (15 mL). The
reaction mixture was stirred for 15 h at RT. The solid was removed by filtration and the
solution was concentrated in vacuo. Purification via flash column chromatography (0-50%
EtOAc/hexanes) afforded the title compound (1.74 g, 75% over two steps) as a clear,
colorless oil. LC-MS m/z 272 (M+H) , 1.22 min (ret time).
Intermediate 11
(2E,4S)({[(1,1-dimethylethyl)oxy]carbonyl}amino)methylheptenoic acid
O N O N
O OH
To a solution of methyl (2E,4S)({[(1,1-dimethylethyl)oxy]carbonyl}amino)
methylheptenoate (5.00 g, 18.43 mmol) in THF (15 mL), MeOH (15.0 mL), and water (15
PU64508
mL) was added LiOH (2.206 g, 92.00 mmol). After stirring for 2 h at RT, the reaction
mixture was concentrated in vacuo. The reaction mixture was acidified with 6 M aq. HCl to
pH = 5 and then extracted with EtOAc. The organic layer was washed with water, dried over
Na SO , filtered, and concentrated in vacuo to afford the title compound (4.7 g, 99%) as a
white semi-solid. LC-MS m/z 158 (M+H-Boc) , 0.94 min (ret time).
Intermediate 12
1,1-dimethylethyl [(1S,2E)(2,3-dihydro-1H-indolyl)(2-methylpropyl)oxo
butenyl]carbamate
O N O N
OH HN N
To a solution of (2E,4S)({[(1,1-dimethylethyl)oxy]carbonyl}amino)methyl
heptenoic acid (4.70 g, 18.26 mmol) in DMF (30.0 mL) were added BOP reagent (8.08 g,
18.26 mmol) and DIPEA (6.38 mL, 36.5 mmol). After stirring at RT for 5 min, 2,3-dihydro-
1H-indole (2.053 mL, 18.26 mmol) was added and stirring continued overnight. The reaction
mixture was diluted with water and extracted with EtOAc. The organic layer was washed
with brine, dried over Na SO , filtered, concentrated in vacuo and purified by flash column
chromatography (0-20% EtOAc/hexanes) to afford the title compound (4.83 g, 74%) as a
white solid. LC-MS m/z 359 (M+H) , 1.18 min (ret time).
Intermediate 13
[(1S,2E)(2,3-dihydro-1H-indolyl)(2-methylpropyl)oxobutenyl]amine
trifluoroacetate
O N HN
To a solution of 1,1-dimethylethyl [(1S,2E)(2,3-dihydro-1H-indolyl)(2-
methylpropyl)oxobutenyl]carbamate (3.21 g, 8.95 mmol) in CH Cl (10.0 mL) was
added TFA (10 mL, 130 mmol). The reaction mixture was stirred for 17.5 h at RT and then
concentrated under reduced pressure and dried under high vacuum to afford the title
compound. LC-MS m/z 259 (M+H) , 0.76 min (ret time).
PU64508
Intermediate 14
1,1-dimethylethyl [4-({[(1S,2E)(2,3-dihydro-1H-indolyl)(2-methylpropyl)
oxobutenyl]amino}carbonyl)tetrahydro-2H-pyranyl]carbamate
O O O
OH HN N
N N O N N
A solution of 50 wt% T3P in EtOAc (1.2 mL, 2.016 mmol) was added dropwise
to a solution of [(1S,2E)(2,3-dihydro-1H-indolyl)(2-methylpropyl)oxo
butenyl]amine trifluoroacetate (500 mg, 1.343 mmol), 4-((tert-
butoxycarbonyl)amino)tetrahydro-2H-pyrancarboxylic acid (329 mg, 1.343 mmol),
and Et N (0.93 mL, 6.71 mmol) in CH Cl (5 mL) at 0 ºC (bath temp). The ice bath was
3 2 2
removed, and the reaction was stirred at RT. After 1 h 20 min, the reaction was washed
with saturated aq. NaHCO (1 x 5 mL) and 10% citric acid (1 x 5 mL). The organic layer
was concentrated under a stream of nitrogen, and the residue was purified by flash
column chromatography, giving 204 mg (31%) of the title compound. LC-MS m/z 486
(M+H) , 1.07 min (ret time).
PU64508
COMPOUNDS OF FORMULA (I)
Example 1
4-amino-N-[(1S,2E)(2,3-dihydro-1H-indolyl)ethyloxobuten
yl]tetrahydro-2H-pyrancarboxamide hydrochloride
O O O
O N H N
A solution of concentrated aq. HCl (0.23 mL, 2.76 mmol) was added to a solution
of 1,1-dimethylethyl [4-({[(1S,2E)(2,3-dihydro-1H-indolyl)ethyloxobuten-
1-yl]amino}carbonyl)tetrahydro-2H-pyranyl]carbamate (251 mg, 0.549 mmol) in
isopropanol (2.5 mL). The reaction flask was fitted with an air condenser, and the
reaction mixture was heated to 65 °C (bath temp) for 1 h 45 min. The solvent was
evaporated under reduced pressure. Water (5 mL) was added to the residue, and the
mixture was concentrated under reduced pressure at 65 ºC. Water (2 mL) was added to
the residue, and the mixture was lyophilized, giving 193.3 mg (89%) of the title
compound. LC-MS m/z 358 (M+H) , 0.68 (ret time). H NMR (400 MHz,
METHANOL-d ) δ ppm 8.14 (br. s., 1 H); 7.25 (d, J=7.03 Hz, 1 H); 7.18 (t, J=7.53 Hz, 1
H); 7.02 - 7.09 (m, 1 H); 6.83 (dd, J=15.18, 6.65 Hz, 1 H); 6.49 (d, J =14.8 Hz, 1 H); 4.56
(d, J=7.28 Hz, 1 H); 4.22 (br. s., 2 H); 3.95 (d, J=7.53 Hz, 1 H); 3.88 - 3.94 (m, 1 H); 3.71
- 3.78 (m, 2 H); 3.23 (br. s., 2 H); 2.39 - 2.46 (m, 2 H); 1.79 - 1.86 (m, 2 H); 1.75 (s, 1 H);
1.72 (d, J=8.28 Hz, 1 H); 1.00 (t, J=7.40 Hz, 3 H).
Example 2
4-amino-N-[(1S,2E)(2,3-dihydro-1H-indolyl)(2-methylpropyl)oxo
butenyl]tetrahydro-2H-pyrancarboxamide hydrochloride
O O O
O N N H N N
A solution of concentrated aq. HCl (0.22 mL, 2.64 mmol) was added to a solution
of 1,1-dimethylethyl [4-({[(1S,2E)(2,3-dihydro-1H-indolyl)(2-methylpropyl)
PU64508
oxobutenyl]amino}carbonyl)tetrahydro-2H-pyranyl]carbamate (251 mg, 0.517
mmol) in isopropanol (2.5 mL). The reaction flask was fitted with an air condenser, and
the reaction mixture was heated to 65 °C (bath temp). After 1 h 45 min, the solvent was
evaporated under reduced pressure at 60 ºC. Water (5 mL) was added to the residue, and
the mixture was concentrated under reduced pressure at 65 ºC. Water (2 mL) was added
to the residue, and the mixture was lyophilized, giving 130.6 mg (60%) of the title
compound. LC-MS m/z 386 (M+H) , 0.79 (ret time). H NMR (400 MHz,
METHANOL-d ) δ ppm 8.15 (d, J=7.03 Hz, 1 H); 7.25 (d, J=7.03 Hz, 1 H); 7.18 (t,
J=7.65 Hz, 1 H); 7.06 (t, J=7.91 Hz, 1 H); 6.81 (dd, J=15.18, 6.40 Hz, 1 H); 6.49 (br. s., 1
H); 4.73 – 4.85 (m, 2 H); 4.21 (t, J=8.28 Hz, 2 H); 3.91 - 3.97 (m, 2 H); 3.70 - 3.77 (m, 2
H); 3.25 – 3.21 (m, 2 H); 2.35 - 2.48 (m, 2 H); 1.82 (d, J=14.31 Hz, 2 H); 1.63 - 1.71 (m,
2 H); 1.50 - 1.57 (m, 1 H); 0.98 (dd, J=11.92, 6.40 Hz, 6 H).
Biological Background:
Biological Assay(s)
The compounds according to Formula (I) are cathepsin C inhibitors, which
indirectly inhibit the activity of serine proteases that are activated by cathepsin C, such as
NE. The compounds according to Formula (I), therefore, are useful in the treatment of
COPD and other conditions involving cathepsin C and/or such serine proteases. The
biological activity of the compounds according to Formula (I) can be determined using
any suitable assay for determining the activity of a candidate compound as a cathepsin C
inhibitor or for determining the ability of a candidate compound to prevent the cathepsin
C mediated activation of certain serine proteases, as well as suitable tissue and in vivo
models.
A. Transpeptidation of Leucine-Leucine-O-Methyl (LLOM) cell-based Luminescence
Viability Assay
Principle:
Cathepsin C has been shown to catalyze the transpeptidation of dipeptidyl methyl-
O –esters within the lysosomes of cells from the monocytic lineage such as HL60, U937
PU64508
or THP1 causing a membranolytic effect that results in cell death (DL. Thiele, P. Lipsky
PNAS 1990 Vol. 87, pp. 83-87). This mechanism was used to assess Cathepsin C in cells
activity in the presence of the compounds of the invention.
Frozen HL-60 cells were resuspended at 1.25 x 10 cells/mL in fresh prewarmed
Iscove’s modified Dulbeccos’ medium (IMDM, contains 25 mM glutamine) with 20 %
FBS. This suspension was dispensed (8 μL) into white low volume 384 well plates.
Plates were previously stamped with 100 nL of compound at a top concentration of 2.5
mM and serially diluted 1:3. Control and blank wells contained 100 nL of DMSO. Each
well then received 2 μL of a fresh 1.25 mM solution of leucine-leucine-OMethyl (LLOM,
Bachem) in IMDM plus 25 mM HEPES (final concentration LLOM 250 μM). The plates
were covered and incubated for 4 h at 37 °C in a 5% CO incubator, then removed and
equilibrated to room temperature for 10 min. Cell viability was determined with a
CellTiter-Glo luminescent assay (Promega) according to the manufacturer’s instructions.
Cell viability was compared to controls containing no LLOM (100 %).
B. Recombinant Cathepsin C in vitro assay:
The activity of recombinant human cathepsin C was measured by the cleavage of
a fluorogenic substrate, H-Ser-Tyr-AMC. Briefly, 24 pM cathepsin C was incubated with
test compound (e.g. inhibitor) in a buffer consisting of 50 mM sodium acetate, 30 mM
sodium chloride, 1 mM CHAPS, 1 mM dithiothreitol, 1 mM EDTA, pH 5.5 at room
temperature for one hour. After one hour of incubating test compound with cathepsin C,
the activity assay was initiated by the addition of an equal volume of 0.010 mM H-Ser-
Tyr-AMC in the same buffer. After one hour, the activity assay was stopped by the
addition of 1/5 volume of 100 μM E-64. The reaction product was measured on a
fluorescence reader set at an excitation wavelength of 360 nm and emission wavelength
of 460 nm and equipped with a 400 nm dichroic mirror.
The compounds of Examples 1 and 2 each exhibited 50% cathepsin C inhibition at
a concentration of less than 1 nM in an average of two experiments.
C. Mouse cigarette smoke exposure in vivo assay:
Mouse cigarette smoke exposure and drug administration:
PU64508
Beginning at 3-4 months of age, female C57BL/6 mice (Jackson Laboratory, Bar
Harbor, ME) received nose-only exposure to 4% cigarette smoke from 3R4F cigarettes
(College of Agriculture, Reference Cigarette Program, University of Kentucky), for 2
h/day, 5 days/week for 18 weeks. Smoke was generated by a Baumgartner-Jaeger CSM
2070i Smoking Machine (CH Technologies Inc., Westwood, NJ). During exposure to
smoke or air (sham controls), mice were maintained in restraining tubes containing
stainless steel nose cone inserts. Two hours following the final smoke exposure,
bronchoalveolar lavage (BAL) fluid (n = 3 per treatment group) was collected. During
the final 6 weeks of the 18 week exposure, mice were administered drug or vehicle alone
(1% methylcellulose/25 mM citrate, pH 4.0) orally, twice daily (at 11 and 13 hour
intervals), 7 days/week. Sham-exposed mice received vehicle alone, while smoke-
exposed mice received one of the following treatments: vehicle alone, the Compound of
Example 1 at 1, 10 or 30 mg/kg, or the Compound of Example 2 at 1, 10 or 30 mg/kg.
Mice received the first daily dose of drug or vehicle alone up to 1 hour prior to the
intiation of smoke/sham exposure.
Bronchoalveolar lavage:
Animals were euthanized using i.p. injection of 0.1ml Fatal Plus (Vortech
Pharmaceuticals, Dearborn, MI) and the trachea cannulated with a 3-in. section of PE90
tubing (BD, Franklin Lakes, NJ), to which was attached a blunted 21-gauge needle
connected to a 3- way stopcock (Baxter Healthcare, Deerfield, IL). Four 1 mL aliquots of
ice cold PBS were injected and removed sequentially through the tubing separately, and
the BAL fluid centrifuged at 140×g for 2 min. Cell pellets isolated from the four aliquots
were combined and total cells counted using a hemocytometer. Differential cell analysis
was performed on cytospins using Wright–Geimsa stain.
Statistical analysis:
Data are presented in Figures 1, 2, and 3 as the mean + S.E.M. Statistical
significance was determined using a one-way ANOVA with a Bonferroni post-test.
Values of p < 0.05 were considered significant. *, p < 0.05; **, p < 0.01; ***, p < 0.001.
Percent values shown indicate percent inhibition of the window between vehicle-
treated/smoke-exposed animals and vehicle-treated/sham-exposed animals.
PU64508
The compounds of the invention are believed to be useful in therapy as defined
above and to not have unacceptable or untoward effects when used in compliance with a
permitted therapeutic regime.
The foregoing examples and assay have been set forth to illustrate the invention,
not limit it. What is reserved to the inventors is to be determined by reference to the
claims.
PU64508
Claims (11)
1. A compound according to Formula (I) or a pharmaceutically acceptable salt thereof: HN N 5 wherein: R and R are each independently selected from the group consisting of hydrogen, (C -C )alkyl, (C -C )alkenyl, (C -C )alkynyl, (C -C )cycloalkyl, (C -C )cycloalkenyl, 1 8 2 8 2 8 3 8 5 8 (C -C )bicycloalkyl, heterocycloalkyl, (C -C )cycloalkyl(C -C )alkyl, 6 10 3 8 1 6 (C -C )cycloalkenyl(C -C )alkyl, heterocycloalkyl(C -C )alkyl, aryl, heteroaryl, 5 8 1 6 1 6 10 aryl(C -C )alkyl, and heteroaryl(C -C )alkyl; 1 6 1 6 wherein any (C -C )alkyl, (C -C )alkenyl, or (C -C )alkynyl is optionally 1 8 2 8 2 8 substituted one to three times, independently, by -CF , cyano, -CO (C -C )alkyl, 3 2 1 4 -CONH(C -C )alkyl, -CON(C -C )alkyl(C -C )alkyl, -SO (C -C )alkyl, 1 4 1 4 1 4 2 1 4 -SO NH(C -C )alkyl, -SO N(C -C )alkyl(C -C )alkyl, amino, (C -C )alkylamino, 2 1 4 2 1 4 1 4 1 4 15 ((C -C )alkyl)((C -C )alkyl)amino, hydroxyl, or (C -C )alkoxy; 1 4 1 4 1 4 and wherein any cycloalkyl, cycloalkenyl, bicycloalkyl, or heterocycloalkyl group is optionally substituted one to three times, independently, by (C -C )alkyl, (C -C )haloalkyl, cyano, -CO (C -C )alkyl, -CONH(C -C )alkyl, 1 4 1 4 2 1 4 1 4 -CON(C -C )alkyl(C -C )alkyl, -SO (C -C )alkyl, -SO NH(C -C )alkyl, 1 4 1 4 2 1 4 2 1 4 20 -SO N(C -C )alkyl(C -C )alkyl, amino, (C -C )alkylamino, 2 1 4 1 4 1 4 ((C -C )alkyl)((C -C )alkyl)amino, hydroxyl, (C -C )alkoxy, aryl, or 1 4 1 4 1 4 aryl(C -C )alkyl, wherein the aryl moiety of said aryl or aryl(C -C )alkyl is 1 4 1 4 optionally substituted one to three times, independently, by halogen, -CF , (C -C )alkyl, hydroxyl, or (C -C )alkoxy; 1 4 1 4 25 and wherein any aryl or heteroaryl group is optionally substituted one to three times, independently, by halogen, (C -C )alkyl, (C -C )cycloalkyl, 1 6 3 6 (C -C )cycloalkenyl, (C -C )haloalkyl, cyano, -CO (C -C )alkyl, 5 6 1 6 2 1 4 -CONH(C -C )alkyl, -CON(C -C )alkyl(C -C )alkyl, -SO (C -C )alkyl, 1 4 1 4 1 4 2 1 4 -SO NH(C -C )alkyl, -SO N(C -C )alkyl(C -C )alkyl, amino, (C -C )alkylamino,
2 1 4 2 1 4 1 4 1 4 PU64508 ((C -C )alkyl)((C -C )alkyl)amino, hydroxyl, (C -C )alkoxy, (C -C )alkylthio-, 1 4 1 4 1 4 1 4 aryl, heteroaryl, aryl(C -C )alkyl, or heteroaryl(C -C )alkyl; 1 4 1 4 wherein any aryl or heteroaryl moiety of said aryl, heteroaryl, aryl(C -C )alkyl, or heteroaryl(C -C )alkyl is optionally substituted one to 1 4 1 4 5 three times, independently, by halogen, -CF , (C -C )alkyl, hydroxyl, or 3 1 4 (C -C )alkoxy; and wherein any (C -C )cycloalkyl is optionally substituted one to three times, independently, by (C -C )alkyl, aryl, or heteroaryl; wherein said aryl or heteroaryl is optionally substituted one 10 to three times, independently, by halogen, -CF , (C -C )alkyl, 3 1 4 hydroxyl, or (C -C )alkoxy; or R and R taken together with the nitrogen to which they are attached represent a 5- to 7-membered saturated or unsaturated ring optionally containing one other heteroatom which is oxygen, nitrogen, or sulfur, wherein said ring is optionally fused to a 15 (C -C )cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring; or R and R taken together with the nitrogen to which they are attached represent a 6- to 10-membered bridged bicyclic ring system optionally fused to a (C -C )cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring; and R is hydrogen, (C -C )alkyl, (C -C )haloalkyl, (C -C )alkenyl, (C -C )alkynyl, 1 8 1 8 2 8 2 8 20 (C -C )cycloalkyl, (C -C )cycloalkenyl, (C -C )cycloalkyl(C -C )alkyl, 3 6 5 6 3 6 1 4 (C -C )cycloalkenyl(C -C )alkyl, or aryl(C -C )alkyl, wherein the aryl moiety of the 5 6 1 4 1 4 aryl(C -C )alkyl is optionally substituted one to three times, independently, by halogen, (C -C )alkyl, or -CF . 1 4 3 25 2. The compound or salt according to Claim 1, wherein R and R taken together with the nitrogen to which they are attached represent a 5- to 7-membered saturated or unsaturated ring optionally containing one other heteroatom which is oxygen, nitrogen, or sulfur; wherein said ring is optionally fused to a (C -C )cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring. PU64508
3. The compound or salt according to Claim 1, wherein R and R taken together with the nitrogen to which they are attached represent a 5- to 6-membered saturated or unsaturated ring optionally fused to a phenyl moiety. 5
4. The compound or salt according to any one of Claims 1-3, wherein R is (C -C )alkyl or (C -C )cycloalkyl(C -C )alkyl. 1 6 3 6 1 2
5. A compound which is 4-amino-N-[(1S,2E)(2,3-dihydro-1H-indolyl)- 1-ethyloxobutenyl]tetrahydro-2H-pyrancarboxamide or a pharmaceutically 10 acceptable salt thereof.
6. A compound which is 4-amino-N-[(1S,2E)(2,3-dihydro-1H-indolyl)- 1-(2-methylpropyl)oxobutenyl]tetrahydro-2H-pyrancarboxamide or a pharmaceutically acceptable salt thereof.
7. A pharmaceutical composition which comprises the compound or salt according to any one of Claims 1-6, and a pharmaceutically acceptable excipient.
8. A process for preparing the composition as defined in claim 7, the process 20 comprising mixing the compound or salt with the pharmaceutically acceptable excipient.
9. The compound or salt according to any one of Claims 1-6 for use in the treatment of chronic obstructive pulmonary disease. 25
10. Use of the compound or salt according to any one of Claims 1-6 in the manufacture of a medicament for use in the treatment of chronic obstructive pulmonary disease.
11. A pharmaceutical composition according to claim 7 substantially as herein 30 described with reference to any example thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161441840P | 2011-02-11 | 2011-02-11 | |
US61/441,840 | 2011-02-11 | ||
PCT/US2012/024428 WO2012109415A1 (en) | 2011-02-11 | 2012-02-09 | Cathepsin c inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ614540A NZ614540A (en) | 2015-03-27 |
NZ614540B2 true NZ614540B2 (en) | 2015-06-30 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL287880B1 (en) | 1r,2s,5s)-n-{(1s)-1-cyano-2-[(3s)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[3-methyl-n- (trifluoroacetyl)-l-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide and pharmaceutical compositions comprising it | |
ES2560612T7 (en) | Benzylamine derivatives as inhibitors of plasma kallikrein | |
JP2010508322A (en) | Novel substituted pyridine derivatives as cysteine protease inhibitors | |
US9187461B2 (en) | Cathepsin C inhibitors | |
JP6408008B2 (en) | Peptidylnitrile compounds as dipeptidylpeptidase I inhibitors | |
JP6441830B2 (en) | Substituted 2-aza-bicyclo [2.2.1] heptane-3-carboxylic acid (cyano-methyl) -amide inhibitors of cathepsin C | |
WO2014091443A1 (en) | Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis | |
JP2018507223A (en) | Peptidylnitrile compounds as dipeptidylpeptidase I inhibitors | |
WO2011025799A1 (en) | Cathepsin c inhibitors | |
CN116813691B (en) | Novel dipeptide compounds and use thereof | |
JP2008531706A (en) | Novel cathepsin C inhibitor and use thereof | |
NZ614540B2 (en) | Cathepsin c inhibitors | |
KR20120061870A (en) | Cathepsin c inhibitors | |
WO2012112733A1 (en) | Cathepsin c inhibitors | |
WO2015032942A1 (en) | N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors | |
EP4357335A1 (en) | Azabicyclo[3.1.0]hexane compound | |
WO2001010844A1 (en) | φ-AMINO-α-HYDROXYCARBOXYLIC ACID DERIVATIVES HAVING INTEGRIN αvβ3 ANTAGONISM |